[go: up one dir, main page]

US20090318443A1 - Kinase inhibitors - Google Patents

Kinase inhibitors Download PDF

Info

Publication number
US20090318443A1
US20090318443A1 US12/509,886 US50988609A US2009318443A1 US 20090318443 A1 US20090318443 A1 US 20090318443A1 US 50988609 A US50988609 A US 50988609A US 2009318443 A1 US2009318443 A1 US 2009318443A1
Authority
US
United States
Prior art keywords
imidazol
mmol
phenyl
imidazo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/509,886
Inventor
Rosanne Bonjouklian
Chafiq Hamdouchi Hamdouchi
Chuan Shih
Alfonso De Dios
Miriam Filadelfa del Prado
Carlos Jaramillo Aguado
Pramila Kotiyan
Mary Margaret Mader
Sheila Pleite Selgas
Concepcion Sanchez-Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090318443(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US12/509,886 priority Critical patent/US20090318443A1/en
Publication of US20090318443A1 publication Critical patent/US20090318443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the p38 kinase is a mitogen-activated protein (MAP) kinase that belongs to the serine/threonine kinase superfamily. This kinase is activated by extracellular stresses such as heat, UV light, and osmotic stress, as well as by inflammatory stimuli such as lipopolysaccharide. When activated, p38 kinase phosphorylates intracellular protein substrates that regulate the biosynthesis of the pro-inflammatory cytokines tumor necrosis factor ⁇ (TNF- ⁇ ) and interleukin-1 ⁇ (IL-1 ⁇ ). These cytokines are implicated in the pathology of a number of chronic inflammatory disorders (Lee, et al., Ann. N.Y.
  • the present invention provides new inhibitors of p38 kinase useful for the treatment of conditions resulting from excessive cytolkine production.
  • the present invention provides compounds of Formula I:
  • the present invention provides a method of inhibiting p-38 kinase ill a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of suppressing the production of tumor necrosis factor ⁇ (TNF- ⁇ ) in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • TNF- ⁇ tumor necrosis factor ⁇
  • the present invention also provides a method of suppressing the production of interleukin-1 ⁇ (IL-1 ⁇ ) in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • IL-1 ⁇ interleukin-1 ⁇
  • the present invention further provides a method of treating conditions resulting from excessive cytokine production in a mammal comprising administering to a mammal in need of such treatment a cytokine-suppressing amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating a susceptible neoplasm in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of inhibiting metastasis in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating rheumatoid arthritis in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical formulation comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of p38 kinase. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the inhibition of p38 kinase in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the inhibition of p38 kinase comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents thereof. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by inhibition of p-38 kinase.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the suppression of the production of tumor necrosis factor ⁇ (TNF- ⁇ . Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the suppression of the production of tumor necrosis factor ⁇ (TNF- ⁇ ) in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the suppression of the production of tumor necrosis factor ⁇ (TNF- ⁇ ) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of the production of tumor necrosis factor ⁇ (TNF- ⁇ ).
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the suppression of the production of interleukin-1 ⁇ (IL-1 ⁇ ). Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the suppression of the production of interleukin-1 ⁇ (IL-1 ⁇ ) in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the suppression of the production of interleukin-1 ⁇ (IL-1 ⁇ ) comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of the production of interleukin-1 ⁇ (IL-1 ⁇ ).
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of conditions resulting from excessive cytokine production. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of conditions resulting from excessive cytokine production in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of conditions resulting from excessive cytokine production comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of excessive cytokine production.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a susceptible neoplasm. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of a susceptible neoplasm in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of a susceptible neoplasm comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of metastasis. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the inhibition of metastasis in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the inhibition of metastasis comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of rheumatoid arthritis. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of rheumatoid arthritis comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • C 1 -C 7 alkyl includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl moieties.
  • C 1 -C 7 alkylene includes methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, hexylene and heptylene moieties.
  • C 3 -C 7 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl moieties.
  • (C 1 -C 7 alkylene)-(C 3 -C 7 cycloalkyl) is taken to mean a C 3 -C 7 cycloalkyl attached through a C 1 -C 7 alkylene linker.
  • halo includes fluoro, chloro, bromo, and iodo.
  • p-38 kinase is taken to mean the p-38 ⁇ and/or p-38 ⁇ kinase isoforms.
  • TNF- ⁇ (IL-1 ⁇ , cytokine)
  • IL-1 ⁇ IL-1 ⁇ , cytokine
  • MED Minimum Effective Dose
  • TED Threshold Effective Dose
  • TMED Threshold Minimum Effective Dose
  • the term “effective amount” is taken to mean a dose of a compound of Formula I necessary to achieve the desired pharmacological effect.
  • certain compounds of Formula I contain at least one chiral center.
  • the present invention contemplates all individual enantiomers or diastereomers, as well as mixtures of the enantiomers and diastereomers of said compounds including racemates. It is preferred that compounds of Formula I containing at least one chiral center exist as single enantiomers or diastereomers.
  • the single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques.
  • Tautomers I and II are structurally distinct, the skilled artisan will appreciate that they exist in equilibrium and are easily and rapidly interconvertible under ordinary conditions. (See: March, Advanced Organic Chemistry , Third Edition, Wiley interscience, New York, New York (1985), pages 66-70; and Allinger, Organic Chemistry , Second Edition, Worth Publishers, New York, New York, (1976), page 173) As such, the representation of a compound of Formula I, where variable “W” is imidazole (i) and R 4 is hydrogen, in one tautomeric form contemplates both tautomeric forms of the imidazole ring.
  • compounds of the present invention are capable of forming salts.
  • the pharmaceutically acceptable salts of all of the compounds are included in the names of them.
  • the compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Preferred pharmaceutically acceptable salts are those formed with maleic acid, fumaric acid, succinic acid, hydrochloric acid, and methanesulfonic acid.
  • di-methanesulfonic acid salts of the compounds of Formula I are especially preferred.
  • Certain classes of compounds of Formula I are preferred inhibitors of p-38 kinase. The following paragraphs describe such preferred classes:
  • X is C-R 1 , R 2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, and R 4 is hydrogen;
  • X is C-NH 2
  • R 2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, and R 4 is hydrogen;
  • X is C-R 1 , R is C 1 -C 7 alkyl, R 2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, R 3 is C 1 -C 7 alkyl or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl, and R 4 is hydrogen;
  • X is C-NH 2 , R is C 1 -C 7 alkyl, R 2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, R 3 is C 1 -C 7 alkyl or phenyl optionally substituted with one or two substituents independently selected from halo, and R 4 is hydrogen;
  • Preferred embodiments of the present invention include all combinations of paragraphs a)-q).
  • each of these compounds exist as the methanesulfonate, succinate, fumarate, dimaleate, dihydrochloride, or dimethanesulfonate salt. It is especially preferred that each of these compounds exist as the dimethanesulfonate salt.
  • die present invention also provides a method of inhibiting p38 kinase in a mammal that comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula I. It is preferred that the mammal to be treated by the administration of the compounds Formula I is human.
  • the compounds of the present invention are useful for suppressing the production of the pro-inflammatory cytokines tumor necrosis factor ⁇ (TNF- ⁇ ) and interleukin-1 ⁇ (IL-1 ⁇ ), and therefore for the treatment of disorders resulting from excessive cytokine production.
  • TNF- ⁇ tumor necrosis factor ⁇
  • IL-1 ⁇ interleukin-1 ⁇
  • Compounds of Formula I are therefore believed to be useful in treating inflammatory disorders, including eczema, atopic dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and toxic shock syndrome.
  • Compounds of the present invention are also believed to be useful in the treatment of cardiovascular disorders, such as acute myocardial infarction, chronic heart failure, atherosclerosis, viral myocarditis, cardiac allograft rejection, and sepsis-associated cardiac dysfunction. Furthermore, compounds of the present invention are also believed to be useful for the treatment of central nervous system disorders, such as meningococcal meningitis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
  • a susceptible neoplasm is defined to be a neoplasm that depends upon p38 kinase for its survival, growth, or metastasis.
  • Susceptible neoplasms include tumors of the brain, genitourinary tract, lymphatic system, stomach, larynx, and lung (U.S. Pat. No. 5,717,100).
  • the term “susceptible neoplasms” as used in the present application includes human cancers including non-small cell lung carcinoma (A. Greenbero, et al., Am. J. Respir. Cell Mol. Biol., 26, 558 (2002)), breast carcinoma (J. Chen, et al., J. Biol. Chem., 276, 47901 (2001); B. Salh, et al., Int. J. Cancer, 98, 148 (2002); and S. Xiono, et al., Cancer Res., 61, 1727 (2001)), gastric carcinoma (Y. D. Jung, et al., Proc. Am. Assoc.
  • inhibition of p38 kinase may be effective in the treatment of certain viral conditions such as influenza (K. Kujime, et al., J. Immunology., 164, 3222-3228 (2000)), rhinovirus (S. Griego, et al., J. Immunology, 165, 5211-5220 (2000)), and HIV (L. Shapiro, et al., Proc. Natl. Acad. Sci. USA, 95, 7422-7426, (1998)).
  • the compounds of the present invention may be prepared by a variety of procedures, some of which are illustrated in the Schemes below. It will be recognized by one of skill in the art that the individual steps in the following schemes may be varied to provide the compounds of Formula I. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties. Some substituents have been eliminated in the following schemes for the sake of clarity and are not intended to limit the teaching of the schemes in any way.
  • Diketone (a) is reacted with ammonium acetate and an appropriate aldehyde in an appropriate solvent, preferably acetic acid, to provide the corresponding nitropyridinyl-imidazole (b).
  • an appropriate solvent preferably acetic acid
  • the nitro moiety is reduced under standard hydrogenation or chemical conditions to provide the corresponding diamine (c).
  • This diamine is then either reacted with cyanogen bromide to provide the 3-substituted-5-(imidazol-4-yl)-2-aminopyridinyl-imidazole (Ia), with an appropriate orthofoimate to provide the 3-substituted-5-(imidazol-4-yl)pyridinylimidazole (Ib), or with an appropriate nitrite to provide the 3-substituted-5-(imidazol-4-yl)pyridinyltriazole (Ic).
  • the requisite diketones (a) may be prepared as described in the following scheme, where R and R 2 are as previously defined.
  • 2,6-dichloronitropyridine (d) and an appropriate amine or amine derivative are heated together in an appropriate solvent to provide the corresponding 2-amino-6-chloro-3-nitropyridine (e), which is then coupled with an appropriately substituted acetylene to provide the corresponding 1,2-disubstituted acetylene (f).
  • This acetylene is oxidized to provide the target diketone (a).
  • Acetylene (f) is treated with mercuric oxide in aqueous sulfuric acid to provide the ketone (g).
  • This ketone is treated with dimethylformamide dimethylacetal or tris(dimethyl-amino)methane in a suitable solvent, typically dimethylformamide, to provide the enaminoketone (h).
  • the enaminoketone is then treated with hydrazine in a suitable solvent, typically ethanol or methanol, to provide the phenylpyrazole (j).
  • the imidazo- or triazolopyridine moiety is prepared as previously described to provide the compounds of Formula Id.
  • the acetylene (f) is reacted with a source of azide, typically sodium azide, in a suitable solvent, such as dimethyoxyethane to provide the triazole (k).
  • a source of azide typically sodium azide
  • a suitable solvent such as dimethyoxyethane
  • the imidazo- or triazolopyridine moiety is prepared as previously described to provide the compounds of Formula Ie.
  • the appropriately substituted heterocycle (o) is reacted with an appropriate boronic acid (p) in the presence of a suitable catalyst as previously described to provide the compounds of Formula If.
  • the requisite ⁇ -bromoketones are either commercially available or may be prepared by standard conditions from the corresponding carbonyl compound, for example, as described by House (H. O. House, Modern Synthetic Reactions, W. A. Benjamin, Inc., Menlo Park, Calif. (1972), pages 459-478) and Larock (R. C. Larock, Comprehensive Organic Transformations , VCH Publishers, Inc., New York, N.Y. (1989), pages 369-471, 755).
  • the requisite amides and thioamides are either commercially available or may be prepared by standard methods well known to the skilled artisan.
  • Additional compounds of Formula I where W is imidazole (i) or isoxazole (vi) may be prepared under standard palladium coupling conditions as described in the following Scheme, where W′ is imidazole (i) or isoxazole (vi), and X and R are as previously defined.
  • An appropriately substituted haloheteroaryl (q) is coupled with an appropriately substituted boronic acid (p) in the presence of a palladium catalyst, typically bis(triphenylphosphine)palladium(II) chloride, in a suitable solvent to provide the desired compound of Formula Ie.
  • a palladium catalyst typically bis(triphenylphosphine)palladium(II) chloride
  • primary and secondary amines may be acylated, alkylated or coupled with carboxylic acids or amino acids under standard peptide coupling conditions.
  • ester moieties may be reduced to the corresponding alcohols or converted to amides under standard conditions.
  • Alcohols may be activated and displaced by a number of nucleophilcs to provide other compounds of the invention.
  • Such leaving groups include but are not limited to halides, oxonium ions, alkyl perchlorates, ammonioalkanesulfonate esters, alkyl fluorosulfonates, nonaflates, tresylates, triflates, and sulfonic esters, preferably the mesylate or tosylate. Techniques for the introduction of these groups are also well known to the skilled artisan; see, for example, March, Advanced Organic Chemistry, 5 th Ed., John Wiley and Sons, New York, pg. 445-449 (2001). Additionally, the 2-amino moiety of the benzimidazole nucleus may be diazotized and displaced to provide additional compounds of the invention under standard conditions.
  • the compounds of Preparations 30-31 may be prepared essentially as described in Preparation 29.
  • the compound of Preparation 34 may be prepared essentially as described in Preparation 33.
  • the compounds of Preparations 38-40 may be prepared essentially as described in Preparation 37.
  • EXAMPLES 2-14 may be prepared essentially as described in 2 0 EXAMPLE 1.
  • EXAMPLES 16-35 may be prepared essentially as described in EXAMPLE 15.
  • EXAMPLES 37-38 may be prepared essentially as described in EXAMPLE 36.
  • EXAMPLES 40-45 may be prepared essentially as described in EXAMPLE 39.
  • EXAMPLE 47-48 may be prepared essentially as described in EXAMPLE 46.
  • EXAMPLE 50-62 may be prepared essentially as described in EXAMPLE 49.
  • the compound of EXAMPLE 64 may be prepared essentially as described in EXAMPLE 63.
  • the compound of EXAMPLE 67 may be prepared essentially as described in EXAMPLE 66.
  • the compounds of EXAMPLE 69-71 may be prepared essentially as described in EXAMPLE 68.
  • the compounds of EXAMPLE 73-75 may be prepared essentially as described in EXAMPLE 72.
  • the compounds of EXAMPLE 77-79 may be prepared essentially as described in EXAMPLE 76.
  • the compounds of EXAMPLE 81-91 may be prepared essentially as described in EXAMPLE 80.
  • the compounds of EXAMPLE 93-96 may be prepared essentially as described in EXAMPLE 92, with the free base converted to the methansutfonate essentially as described in EXAMPLE 1.
  • the compound in EXAMPLE 98 may be prepared essentially as described in EXAMPLE 97, with the free base converted to the methanesulfonate essentially as described in EXAMPLE 1.
  • a master plate is prepared with 250 ⁇ L of the free base of the subject compound in methanol (0.1 M) added to all wells set in a 96 well format.
  • An array of acids is dispensed to each well in one and two molar equivalents.
  • the solvents are evaporated from all 96 wells using a Genevac Series II evaporator leaving solid residue in the master plate.
  • An array of solvents is dispensed to each one of these wells through a cap mat and then heated to 55° C. with stifling and allowed to equilibrate for 60-90 minutes at about 55° C. Each sample is then filtered hot and transferred to corresponding wells in an evaporation plate, a precipitation plate, and a cooling plate.
  • the evaporation plate is prepared by transferring 200 ⁇ L of the filtrate from the master plate using 55° C. heated syringes to the open well titer plate and is then allowed to evaporate to dryness over night at room temperature and ambient humidity.
  • the precipitation plate is prepared by adding 100 ⁇ L of the filtrate from the master plate using 55° C. heated syringes to capped 96 well titer plate where each well contains an anti-solvent of 200 ⁇ L of heptane or 2-propanol.
  • the cooling plate is prepared by transferring 200 ⁇ L of the filtrate from the master plate to individual wells using 55° C. heated syringes in a capped titer plate, and cooling exponentially from 55 to 10° C. over a period of 8 hours.
  • Photomicrographs are collected on the material at the bottom of each well in the 96 well plates using a Zeiss Axiovert 200M inverted incident-light microscope with a 2.5 ⁇ objective. If the material is crystalline, it exhibits birefringence that is displayed as white against a dark background. Amorphous solids appear dark or as opaque droplets or rings.
  • the kinase buffer solution is prepared by combining 2.5 mL 1 M Tris-HCl (pH 7.5), 0.1 mL 1 M dithiothreitol, 1.0 mL 1 M magnesium chloride, and 300 ⁇ L 1% Triton X-100 and diluting to 100 mL with water. 84 mL of this kinase buffer solution is combined with 16 mL DMSO to prepare the 16% DMSO solution.
  • the 200 ⁇ M ATP solution is prepared by adding 102.6 ⁇ L 10 mM aqueous ATP, 25 ⁇ L 33 P-ATP, and 163.5 ⁇ L of 4 mM aqueous Epidermal Growth Factor Peptide 661-681 (Biomol, Catalog #P-121) in 5 mL kinase buffer solution.
  • p38 kinase enzyme solution is prepared by dissolving 9.5 ⁇ L concentrated enzyme solution (250 ng p38 enzyme/ ⁇ L kinase buffer solution) in 1536 ⁇ L kinase buffer solution.
  • test compound and control compound are prepared by dissolving 2 ⁇ L of a 10 mM stock solution of the respective compounds in dimethylsulfoxide in 248 ⁇ L of the 16% DMSO solution in a Costar 96-well microtiter plate. The plate is placed onto the Tecai Genesis automated liquid handler for 1:3 serial dilutions.
  • the plates are allowed to set for 30 min at RT and then washed/aspirated on the Titertek MAP extractor with freshly prepared 0.5% glacial AcOH (1 ⁇ 300 ⁇ L, 2 ⁇ 200 ⁇ L).
  • the wells are blotted and 100 ⁇ L MicroScint-20 scintillation fluid (Packard Bioscience) is added with the Multidrop.
  • the plates are allowed to sit for 30 min and counted on a PE/Wallac Microbeta Trilux scintillation counter for 33 P-isotope.
  • All exemplified compounds were initially tested at 10 concentrations (20 ⁇ M-1 nM using 1:3 serial dilutions). Compounds with IC 50 values less than 25 nM were re-tested at a starting concentration of 2 H to 0.1 nM (1:3 serial dilutions). IC 50 values were calculated (IDBS ActivityBase software) for each compound using non-linear regression. All exemplified compounds were tested essentially as described above and were found to inhibit the p38 kinase enzyme with an IC 50 ⁇ 5 ⁇ M. Specifically, the following compounds were tested essentially as described above and were found to inhibit the p38 kinase enzyme as tabulated below.
  • 1 mL thioglycolate broth (5.0 g yeast extract, 15.0 g casitone or trypticase, 5.0 g dextrose, 2.5 g sodium chloride, 0.75 g L-cystine, 0.5 g sodium thioglycolate, 1.0 mg resazurin, and 0.75 g agar in 1.0 L distilled water) is injected into the peritoneal cavity of Balb/C female mice. At day 4 or 5 post-injection the mice are sacrificed and then injected i.p. with 4 mL RPMI-1640 medium (BioWhittaker) and the peritoneal macrophages are withdrawn by syringe.
  • 4 RPMI-1640 medium BioWhittaker
  • Mouse peritoneal microphages are counted with a hemocytometer and adjusted to 5 ⁇ 10 5 cells/well in 96-well plates in RPMI-1640 medium with 10% fetal bovine serum. 200 ⁇ L/well is plated in 96-well plates and the cells allowed to settle and adhere to the bottom of the well for at least 3 h.
  • the test compound or standard p38 kinase inhibitor is pre-treated using a series of 8 concentrations for 1 h at 37° C. (20 ⁇ L/well).
  • the cells are treated with a mixture of 50 ng/mL lipopolysaccharide (LPS) and 10 U/mL interferon- ⁇ for 18 h at 37° C. (20 ⁇ L/well).
  • the conditioned media is harvested and assayed for TNF- ⁇ production using the Luminex procedure.
  • the lyophilized premixed TNF- ⁇ standard (1 standard tube/two 96-well plates) is reconstituted with 50 ⁇ L sterile water (500,000 pg/mL).
  • the samples are vortexed for 5 seconds, incubated on ice for 30 min, and vortexed for 5 seconds before use.
  • a set of twelve 1.5 m tubes are labeled with #1-thru #12 and then the amounts of cell media shown below added to the appropriate tubes (standard concentrations are as follows: 50,000; 25,000; 12,500; 6,250; 3,125; 1,562.5; 781.3; 390.6; 195.3; 97.7; 48.8; and 24.4 pg/ml).
  • the premixed anti-cytokine conjugated beads are vortexed (25 ⁇ ) vigorously for 30 seconds.
  • the anti-cytokine conjugated beads are diluted to a 1 ⁇ concentration using 1 ⁇ Bio-Plex Assay Buffer.
  • 240 ⁇ L of the pre-mixed beads is added to 5760 ⁇ L of Bio-Plex Assay Buffer.
  • a Millipore 96-well filter plate is blocked with 100 ⁇ L/well of blocking buffer.
  • the blocking buffer is filtered through using a Millipore filtration system and then toweled dry. 2 washes are performed on the filter plate with 100 ⁇ l/well of Bio-Plex Assay Buffer and toweled dry.
  • the 1 ⁇ anti-cytokine conjugated beads are vortexed for 15 seconds and added 50 ⁇ L to each well.
  • cytokine detection antibody 50 ⁇ L of cytokine detection antibody is added and incubated for 60 seconds at RT on a shaker protected from light at setting 6 and then for 30 min at setting 3.3 washes are performed with the Bio-Plex Wash Buffer. This is filtered through and toweled dry.
  • Strept-PE ( ⁇ 10 minutes prior to use) is prepared for every plate and 60 ⁇ L to 5940 ⁇ L of Bio-Plex Assay Buffer added. 50 ⁇ L of Streptavidin-PE is added to each well and incubated for 60 seconds at RT on a shaker protected from light at setting 6 and then for 10 min at setting 3.3 washes are performed with Bio-Plex Wash Buffer. This is filtered through.
  • the beads are re-suspended in 100 ⁇ L/well of Bio-Plex Assay Buffer. Standards and samples are read on a Luminex machine. These intensity readings are then converted to picogram/milliliter units based on a 12-point standard curve created in duplicate using a four-parameter logistic regression method (Bio-Plex Manager 2.0, Bio-Rad), and the IC 50 calculated.
  • Representative members of the exemplified compounds were tested essentially as described above and suppressed TNF- ⁇ in vitro with an IC 50 ⁇ 100 nM. Specifically, the following compounds were tested essentially as described above and were found to suppress TNF- ⁇ in vitro as tabulated below.
  • LPS lipopolysaccharide
  • Representative members of the exemplified compounds were tested essentially as described above and suppressed TNF- ⁇ in vivo with an IC 50 ⁇ 100 mg/kg.
  • the compound of EXAMPLE 104 was tested essentially as described above and exhibited an IC 50 ⁇ 1 mg/kg.
  • Intra-articular injection of LPS into rat ankles induces the synthesis of TNF- ⁇ , which can be measured in synovial lavage fluid. High levels of TNF- ⁇ are detectable within 2 hours. Since the joint is the site where arthritis develops, this model can rapidly determine whether an orally administered compound has an effect on an inflammatory response in the synovium.
  • TNF- ⁇ is measured with a commercially available ELISA kit (R&D, RTA00). Treatment with the compound of EXAMPLE 104 produced a dose-dependent inhibition of TNF- ⁇ synthesis with TMED 50 of 0.54 mg/kg.
  • the B 16F10 melanoma cell line is obtained from the American Type Culture Collection, Rockville, Md.
  • the cells are cultured in RPMI-1640 medium supplemented with 10% fetal calf serum.
  • the cells grown in vitro are harvested during their exponential growth phase by gentle trypsinization, washed twice in medium, and resuspended in serum-free RPMI-1640 medium.
  • the number of viable cells is determined using a hemocytometer and adjusted to 1 ⁇ 10 7 /mL.
  • Tumor cells are injected subcutaneously in normal C57B16 mice. hioculum volume per mouse is 0.2 mL (2,000,000 cells). When the tumors reach 300-500 mg, the mice are used for target inhibition studies at either a fixed time (2.5 hours) after p.o. compound treatment or pharmacodynamic studies where the tumors are collected at multiple time-points (e.g., 3, 6, 9, 12, 15, and 18 h) after p.o. compound treatment.
  • Tumors collected as described above are immediately snap-frozen in liquid nitrogen and stored at ⁇ 80° C.
  • Tumor tissues are homogenized on ice using a Daunce homogogenizer in an extraction buffer (25 mM Tris pH 7.5 containing the following protease inhibitors: 10 ⁇ g/mL leupeptin, 10 ⁇ g /mL soybean tryp-chymotrypsin inhibitor, 10 ⁇ g/mL N-tosyl-L-phenylalanine chloromethyl ketone, 10 ⁇ g/mL aprotinin, N ⁇ -p-tosyl-L-arginine methyl ester, 7 mM benzamidine, 0.3 mM phenylmethylsulfonyl fluoride and two tablets of Roche complete protease inhibitor cocktail; following phosphatase inhibitors: 60 mM beta-glycerophosphate, 1 mM sodium vanadate, 10 mM sodium fluoride.
  • Tissue lysates are cleared by centrifugation in a refrigerated microcentrifuge at 14,000 rpm and at 1° C. for 20 min. Supernatants are transferred to fresh microfuge tubes prechilled on ice and snap-freeze again in liquid nitrogen or dry ice. After quick thaw to about 80% completion in lukewarm water, the samples are placed on ice to complete thaw. The samples are centrifuged again at 14,000 rpm and at 1° C. for 15 min. The supernatant is transferred to fresh prechilled microfuge tubes and protein concentrations are measured using Bio-Rad protein assay reagents using bovine serum albumin as protein standard.
  • NC nitrocellulose
  • Membranes are washed 4 ⁇ , 10 min each, with TBST. The membranes are then incubated for 40 min with secondary antibody HRP (horse radish peroxidase) conjugate at 1:10,000 dilution in 3% non-fat milk in TBST and washed again 4 times with TB ST, 10 min each. The immuno-blots are then visualized by enhanced chemiluminescence (ECL, Amersham) as per manufacturer's instructions. All primary antibodies are purchased from Cell Signaling and secondary antibody HRP conjugates are obtained from Amersham. Gels, membranes and apparatus used for electrophoresis and Western blotting are purchased from Invitrogen. Protein bands of interest are quantified from films using Kodak Image Station 1000.
  • mice Female Lewis rats ( ⁇ 190 g, Charles River Labs) are immunized with Bovine type II collagen (2 mg/mL) emulsified with an equal volume of adjuvant (aluminum hydroxide). were used. The rats are immunized with approximately 0.3 mg of the emulsion intradermally on the back near the base of the tail. All animals are re-immunized 7 days later according to the same protocol. The rats begin to develop arthritis (characterized by swellling and redness of one or both ankles) from 12 to 14 days after the first immunization. The rats are equally distributed into five treatment groups at the first signs of arthritis and treatment is initiated with each rat dosed bid for 14 days.
  • arthritis characterized by swellling and redness of one or both ankles
  • Group 1 Vehicle 1% NaCarboxymethylcellulose + 0.25% Tween 80 1 mL, PO, Bid ⁇ 14 days
  • Group 2 Test compound 5 mg/kg, 1 mL, PO, Bid ⁇ 14 Group 3 Test compound, 15 mg/kg, 1 mL, PO, Bid ⁇ 14 Group 4 Test compound, 30 mg/kg, 1 mL, PO, Bid ⁇ 14 Group 5 Prednisolone 10 mg/kg, 1 mL, PO, qd ⁇ 14
  • Ankle diameter is measured with calipers 5 days a week and recorded. Data is expressed as the area under the curve (AUC) generated from the composite inflammation scores and statistical analysis performed.
  • Oral administration of the compounds of the present invention is preferred.
  • oral administration is not the only route or even the only preferred route.
  • transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine, and the intravenous route may be preferred as a matter of convenience or to avoid potential complications related to oral administration.
  • Compounds of Formula I may also be administered by the percutaneous, intramuscular, intranasal or intrarectal route in particular circumstances.
  • the route of administration may be varied in any way, limited by the physical properties of the drugs, the convenience of the patient and the caregiver, and other relevant circumstances ( Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).
  • the pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art.
  • the carrier or excipient may be a solid, semi-solid, or liquid material that can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art.
  • the pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants. suppositories, solutions, suspensions, or the like.
  • the compounds of the present invention may be administered orally, for example, with an inert diluent or capsules or compressed into tablets.
  • the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.
  • These preparations should contain at least 4% of the compound of the present invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit.
  • the amount of the compound present in compositions is such that a suitable dosage will be obtained.
  • Preferred compositions and preparations of the present invention may be determined by methods well known to the skilled artisan.
  • the tablets, pills, capsules, troches, and the like may also contain one or more of the following adjuvants: binders such as povidone, hydroxypropyl cellulose, microcrystalline cellulose, or gelatin; excipients or diluents such as: starch, lactose, microcrystalline cellulose or dicalcium phosphate, disintegrating agents such as: croscarmellose, crospovidone, sodium starch glycolate, corn starch and the like; lubricants such as: magnesium stearate, stearic acid, talc or hydrogenated vegetable oil; glidants such as colloidal silicon dioxide; wetting agents such as: sodium lauryl sulfate and polysorbate 80; and sweetening agents such as: sucrose, aspartame or saccharin may be added or a flavoring agent such as: peppermint, methyl salicylate or orange flavoring.
  • binders such as povidone, hydroxypropyl cellulose, microcrystalline cellulose, or gelatin
  • the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.
  • a liquid carrier such as polyethylene glycol or a fatty oil.
  • Other dosage unit forms may contain other various materials that modify the physical form of the dosage unit, for example, as coatings.
  • tablets or pills may be coated with sugar, hydroxypropyl methylcellulose, polymethacrylates, or other coating agents.
  • Syrups may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
  • the compounds of Formula I are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 0.0001 to about 30 mg/kg of body weight.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
  • the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides kinase inhibitors of Formula I.
Figure US20090318443A1-20091224-C00001

Description

    BACKGROUND OF THE INVENTION
  • The p38 kinase is a mitogen-activated protein (MAP) kinase that belongs to the serine/threonine kinase superfamily. This kinase is activated by extracellular stresses such as heat, UV light, and osmotic stress, as well as by inflammatory stimuli such as lipopolysaccharide. When activated, p38 kinase phosphorylates intracellular protein substrates that regulate the biosynthesis of the pro-inflammatory cytokines tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β). These cytokines are implicated in the pathology of a number of chronic inflammatory disorders (Lee, et al., Ann. N.Y. Acad. Sci., 696, 149-170 (1993); Muller-Ladner, Curr. Opin. Rheumatol., 8, 210-220 (1996)), cardiovascular and central nervous system disorders (Salituro, et al., Current Medicinal Chemistry, 6, 807-823 (1999)), and autoimmune disorders (Pargellis, et al, Nature Structural Biology, 9(4), 268-272 (2002)).
  • A number of compounds within the pyridinylimidazole (WO9621452, WO9725045, U.S. Pat. No. 5,656,644, U.S. Pat. No. 5,686,455, U.S. Pat. No. 5,717,100, WO9712876, WO9821957, WO9847892, WO99903837, WO9901449, W00061576, WO0172737) and pyrimidinylimidazole (WO9725048, WO9901452, WO9725046, WO9932121, WO9901131, WO9901130, WO9901136, WO9807452, WO9747618, WO9856788, WO9857996) structural platforms have been identified as inhibitors of p38 kinase or as cytokine inhibitors. Selective inhibitors of p38 kinase are known to suppress the expression of TNF-α and IL-1β (McKenna, et al., J. Med. Chem., 45(11), 2173-2184 (2002)). Anti-inflammatory activity for compounds within the pyrimidinylimidazole structural platform has been reported (Lantos, et al., J. Med. Chem., 27, 72-75 (1984)), and a number of inhibitors of p38 kinase are under active investigation for the treatment of a variety of disorders (Boehm and Adams, Exp. Opin. Ther. Patents, 10(1), 25-37 (2000)). There remains a need for treatment in this field for compounds that are cytokine suppressive drugs, i.e., compounds that are capable of inhibiting p38 kinase.
  • The present invention provides new inhibitors of p38 kinase useful for the treatment of conditions resulting from excessive cytolkine production.
    • BRIEF SUMMARY OF THE INVENTION
  • The present invention provides compounds of Formula I:
  • Figure US20090318443A1-20091224-C00002
  • where:
      • W is:
  • Figure US20090318443A1-20091224-C00003
      • X is N, or C-R1;
      • R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
      • R1 is hydrogen, amino, methyl, or —N=CH(NMe)2;
      • R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
      • R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
      • R4 is hydrogen or C1-C7 alkyl;
      • R5 and R6 are independently selected from the group consisting of C1-C7 alkyl; or a pharmaceutically acceptable salt thereof.
  • The present invention provides a method of inhibiting p-38 kinase ill a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a method of suppressing the production of tumor necrosis factor α (TNF-α) in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a method of suppressing the production of interleukin-1 β (IL-1 β) in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention further provides a method of treating conditions resulting from excessive cytokine production in a mammal comprising administering to a mammal in need of such treatment a cytokine-suppressing amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a method of treating a susceptible neoplasm in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a method of inhibiting metastasis in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a method of treating rheumatoid arthritis in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • The present invention also provides a pharmaceutical formulation comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of p38 kinase. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the inhibition of p38 kinase in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the inhibition of p38 kinase comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents thereof. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by inhibition of p-38 kinase.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the suppression of the production of tumor necrosis factor α (TNF-α. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the suppression of the production of tumor necrosis factor α (TNF-α) in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the suppression of the production of tumor necrosis factor α (TNF-α) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of the production of tumor necrosis factor α (TNF-α).
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the suppression of the production of interleukin-1 β(IL-1 β). Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the suppression of the production of interleukin-1 β (IL-1 β) in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the suppression of the production of interleukin-1 β (IL-1 β) comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of the production of interleukin-1 β (IL-1 β).
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of conditions resulting from excessive cytokine production. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of conditions resulting from excessive cytokine production in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of conditions resulting from excessive cytokine production comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents. The invention also provides the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by suppression of excessive cytokine production.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a susceptible neoplasm. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of a susceptible neoplasm in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of a susceptible neoplasm comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of metastasis. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the inhibition of metastasis in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the inhibition of metastasis comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • This invention also provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of rheumatoid arthritis. Additionally, this invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis in mammals. Furthermore, this invention provides a pharmaceutical composition adapted for the treatment of rheumatoid arthritis comprising a compound of Formula I or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The general chemical terms used in the formulae above have their usual meanings. For example, the term “C1-C7 alkyl” includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl moieties. The term “C1-C7 alkylene” includes methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, hexylene and heptylene moieties. The term “C3-C7 cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl moieties. The term “(C1-C7 alkylene)-(C3-C7 cycloalkyl)” is taken to mean a C3-C7 cycloalkyl attached through a C1-C7 alkylene linker. The term “halo” includes fluoro, chloro, bromo, and iodo.
  • The term “p-38 kinase” is taken to mean the p-38 α and/or p-38 β kinase isoforms.
  • The term “suppressing the production of TNF-α (IL-1 β, cytokine)” is taken to mean decreasing of excessive in vivo levels of TNF-α, IL-1 β, or another cytokine in a mammal to normal or sub-normal levels. This may be accomplished by inhibition of the in vivo release of TNF-α, IL-1 β, or another cytokine by all cells, including macrophages; by down regulation, at the genomic level, of excessive in vivo levels of TNF-α, IL-1 β, or another cytokine in a mammal to normal or sub-normal levels; by inhibition of the synthesis of TNF-α, IL-1 β, or another cytokine as a posttranslational event; or by a down regulation of TNF-α, IL-1 β, or another cytokine at the translational level.
  • The term “Minimum Effective Dose (MED)” is taken to mean the smallest dose that produces an effect that is statistically significantly different from the effect observed in a vehicle control group.
  • The term “Threshold Effective Dose (TED)” is taken to mean the dose required to achieve a specified threshold of activity. For example, the TED50 is the dose required to achieve a response of 50%.
  • The term “Threshold Minimum Effective Dose (TMED)” is taken to mean the lowest dose that guarantees a statistically significant effect that also achieves a specified threshold level of activity. For example, the TMED50 is the lowest dose that achieves a 50% response and is certain to be statistically significantly different from a vehicle control group.
  • The term “effective amount” is taken to mean a dose of a compound of Formula I necessary to achieve the desired pharmacological effect.
  • The skilled artisan will appreciate that certain compounds of Formula I contain at least one chiral center. The present invention contemplates all individual enantiomers or diastereomers, as well as mixtures of the enantiomers and diastereomers of said compounds including racemates. It is preferred that compounds of Formula I containing at least one chiral center exist as single enantiomers or diastereomers. The single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques.
  • The skilled artisan will also appreciate that when variable “W” is imidazole (i), and R4 is hydrogen, the imidazole ring exists in the following two tautomeric forms:
  • Figure US20090318443A1-20091224-C00004
  • Although Tautomers I and II are structurally distinct, the skilled artisan will appreciate that they exist in equilibrium and are easily and rapidly interconvertible under ordinary conditions. (See: March, Advanced Organic Chemistry, Third Edition, Wiley interscience, New York, New York (1985), pages 66-70; and Allinger, Organic Chemistry, Second Edition, Worth Publishers, New York, New York, (1976), page 173) As such, the representation of a compound of Formula I, where variable “W” is imidazole (i) and R4 is hydrogen, in one tautomeric form contemplates both tautomeric forms of the imidazole ring. Likewise, the naming of a compound of Formula I where “W” is imidazole (i) and R4 is hydrogen as either a 1H-imidazole or a 3H-imidazole contemplates both tautomeric forms of the imidazole ring. Specifically, the name 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3 -(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine contemplates the molecule in either the 1H-imidazol-4-yl or 3H-imidazol-4-yl form. Similarly, when variable “W” is triazole (iv), the triazole moiety exists in three tautomeric forms, and the representation or naming of one tautomeric form contemplates all three tautomeric forms of the triazole ring.
  • It will be understood by the skilled reader that compounds of the present invention are capable of forming salts. In all cases, the pharmaceutically acceptable salts of all of the compounds are included in the names of them. The compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Preferred pharmaceutically acceptable salts are those formed with maleic acid, fumaric acid, succinic acid, hydrochloric acid, and methanesulfonic acid. Especially preferred are di-methanesulfonic acid salts of the compounds of Formula I.
  • Certain classes of compounds of Formula I are preferred inhibitors of p-38 kinase. The following paragraphs describe such preferred classes:
      • a) W is:
  • Figure US20090318443A1-20091224-C00005
      • b) W is:
  • Figure US20090318443A1-20091224-C00006
      • c) X is C-R1;
      • d) X is C-NH2;
      • e) R2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl;
      • f) R2 is phenyl;
      • g) R2 is 4-fluorophenyl;
      • h) R2 is 2,4-difluorophenyl;
      • i) R4 is hydrogen;
      • j) W is
  • Figure US20090318443A1-20091224-C00007
  • X is C-R1, R2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, and R4 is hydrogen;
      • k) W is
  • Figure US20090318443A1-20091224-C00008
  • X is C-NH2, R2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, and R4 is hydrogen;
      • l) W is
  • Figure US20090318443A1-20091224-C00009
  • X is C-R1, R is C1-C7 alkyl, R2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, R3 is C1-C7 alkyl or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl, and R4 is hydrogen;
      • m) W is
  • Figure US20090318443A1-20091224-C00010
  • X is C-NH2, R is C1-C7 alkyl, R2 is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl, R3 is C1-C7 alkyl or phenyl optionally substituted with one or two substituents independently selected from halo, and R4 is hydrogen;
      • n) The compound of Formula I is a free base.
      • o) The compound of Formula I is a salt.
      • p) The compound of Formula I is a methanesulfonate salt.
      • q) The compound of Formula I is a di-methanesulfonate salt.
  • Preferred embodiments of the present invention include all combinations of paragraphs a)-q).
  • An especially preferred subgenus of compounds within the scope of Formula I are compounds of Formula I′:
  • Figure US20090318443A1-20091224-C00011
  • where:
      • R1 is 2,2-dimethylpropyl or 1,2,2-trimethylpropyl;
      • R2′ is phenyl, 4-fluorophenyl, or 2,4-difluorophenyl;
      • R3′ is tert-butyl, 2-chloro-6-fluorophenyl, 2-fluoro-6-trifluoromethylphenyl, 2,6-dichlorophenyl, or 2,6-difluorophenyl; or a pharmaceutically acceptable salt thereof.
  • Most preferred compounds of Formula I′ are those where:
        • 1. R′ is 2,2-dimethylpropyl R2′ is 4-fluorophenyl, and R3′ is 2-fluoro-6-trifluoromethylphenyl;
        • 2. R′ is 2,2-dimethylpropyl, R2′ is 4-fluorophenyl, and R3′ is 2,6-dichlorophenyl;
        • 3. R′ is 2,2-dimethylpropyl, R2′ is 4-fluorophenyl, and R3′ is tert-butyl;
        • 4. R′ is 2,2-dimethylpropyl, R2′ is phenyl, and R3′ is 2-chloro-6-fluorophenyl;
        • 5. R′ is 2,2-dimethylpropyl, R2′ is 2,6-difluorophenyl, and R3′ is tert-butyl;
        • 6. R′ is 1,2,2-trimethylpropyl, R2′ is 4-fluorophenyl, and R3′ is tert-butyl; and
        • 7. R′ is 1,2,2-trimethylpropyl, R2′ is 4-fluorophenyl, and R3′ is 2,6-difluorophenyl.
  • It is also preferred that each of these compounds exist as the methanesulfonate, succinate, fumarate, dimaleate, dihydrochloride, or dimethanesulfonate salt. It is especially preferred that each of these compounds exist as the dimethanesulfonate salt.
  • The compounds of Formula I are inhibitors of p38 kinase. Thus, die present invention also provides a method of inhibiting p38 kinase in a mammal that comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula I. It is preferred that the mammal to be treated by the administration of the compounds Formula I is human.
  • As inhibitors of p38 kinase, the compounds of the present invention are useful for suppressing the production of the pro-inflammatory cytokines tumor necrosis factor α (TNF-α) and interleukin-1 β (IL-1 β), and therefore for the treatment of disorders resulting from excessive cytokine production. Compounds of Formula I are therefore believed to be useful in treating inflammatory disorders, including eczema, atopic dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and toxic shock syndrome. Compounds of the present invention are also believed to be useful in the treatment of cardiovascular disorders, such as acute myocardial infarction, chronic heart failure, atherosclerosis, viral myocarditis, cardiac allograft rejection, and sepsis-associated cardiac dysfunction. Furthermore, compounds of the present invention are also believed to be useful for the treatment of central nervous system disorders, such as meningococcal meningitis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
  • Most solid tumors increase in mass through the proliferation of malignant cells and stromal cells, including endothelial cells. In order for a tumor to grow larger than 2-3 millimeters in diameter, it must form a vasculature, a process known as angiogenesis.
  • Suppression of tumor-induced angiogenesis by angiostatin and endostatin has been reported to result in antitumor activity (O'Reilly, et al., Cell, 88, 277-285 (1997)). The selective p38 kinase inhibitor SB22025 has been shown to inhibit angiogenesis (J. R. Jackson, et al., J. Pharmacol. Exp. Therapeutics, 284, 687 (1998)). Because angiogenesis is a critical component of the mass expansion of most solid tumors, the development of new p38 kinase inhibitors for the inhibition of this process represents a promising approach for antitumor therapy. This approach to antitumor therapy may lack the toxic side effects or drug resistance-inducing properties of conventional chemotherapy (Judalh Folkman, Endogenious Inhibitors of Angiogelesis, The Harvey Lectures, Series 92, pages 65-82, Wiley-Liss AIc., (1998)).
  • As inhibitors of p38 kinase, compounds of the present invention, therefore, are also useful in inhibiting growth of susceptible neoplasms. Schultz, R. M. Potential of p38 MAP kinase inhibitors in the the treatment of cancer. In: E. Jucker (ed.), Progress in Drug Research, 60, 59-92, (2003). A susceptible neoplasm is defined to be a neoplasm that depends upon p38 kinase for its survival, growth, or metastasis. Susceptible neoplasms include tumors of the brain, genitourinary tract, lymphatic system, stomach, larynx, and lung (U.S. Pat. No. 5,717,100). Preferably, the term “susceptible neoplasms” as used in the present application includes human cancers including non-small cell lung carcinoma (A. Greenbero, et al., Am. J. Respir. Cell Mol. Biol., 26, 558 (2002)), breast carcinoma (J. Chen, et al., J. Biol. Chem., 276, 47901 (2001); B. Salh, et al., Int. J. Cancer, 98, 148 (2002); and S. Xiono, et al., Cancer Res., 61, 1727 (2001)), gastric carcinoma (Y. D. Jung, et al., Proc. Am. Assoc. Cancer Res., 43, 9 (2002)), colorectal carcinomas (S. Xiong, et al., Cancer Res., 61, 1727 (2001)), prostate carcinomas (J-I Park, et al., Oncogene, 22, 4314-4332 (2003); L. Chen, et al., Cancer Lett., 215, 239-247 (2004); and A. R. Uzgara, et al., Prostate, 55, 128-139 (2003)), malignant melanoma (C. Denkert, et al., Clin. Exp. Metastasis, 19, 79 (2002)), and multiple myeloma (Hideshima, et al., Oncozene advance online publication, 1-11, (Oct. 11, 2004); and flideshima, et al., Blood, 101(2), 703 (2003)).
  • Inhibition of angiogeniesis by suppression of TNF-α has also been taught to be useful in the inhibition or prevention of metastasis (U.S. Pat. No. 6,414,150; U.S. Pat. No. 6,335,336). Furthermore, suppression of TNF-α is indicated for the treatment and prevention of cachexia, a wasting syndrome experienced by about half of all cancer patients (T. Yoneda, et al., J. Clin. Invest., 87, 977 (1991)).
  • Furthermore, inhibition of p38 kinase may be effective in the treatment of certain viral conditions such as influenza (K. Kujime, et al., J. Immunology., 164, 3222-3228 (2000)), rhinovirus (S. Griego, et al., J. Immunology, 165, 5211-5220 (2000)), and HIV (L. Shapiro, et al., Proc. Natl. Acad. Sci. USA, 95, 7422-7426, (1998)).
  • The compounds of the present invention may be prepared by a variety of procedures, some of which are illustrated in the Schemes below. It will be recognized by one of skill in the art that the individual steps in the following schemes may be varied to provide the compounds of Formula I. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties. Some substituents have been eliminated in the following schemes for the sake of clarity and are not intended to limit the teaching of the schemes in any way.
  • Compounds of Formula I where W is the imidazole (i) may be prepared as illustrated in the following scheme where R, R1, R2, and R3 are as previously defined.
  • Figure US20090318443A1-20091224-C00012
  • Diketone (a) is reacted with ammonium acetate and an appropriate aldehyde in an appropriate solvent, preferably acetic acid, to provide the corresponding nitropyridinyl-imidazole (b). The nitro moiety is reduced under standard hydrogenation or chemical conditions to provide the corresponding diamine (c). This diamine is then either reacted with cyanogen bromide to provide the 3-substituted-5-(imidazol-4-yl)-2-aminopyridinyl-imidazole (Ia), with an appropriate orthofoimate to provide the 3-substituted-5-(imidazol-4-yl)pyridinylimidazole (Ib), or with an appropriate nitrite to provide the 3-substituted-5-(imidazol-4-yl)pyridinyltriazole (Ic).
  • The requisite diketones (a) may be prepared as described in the following scheme, where R and R2 are as previously defined.
  • Figure US20090318443A1-20091224-C00013
  • 2,6-dichloronitropyridine (d) and an appropriate amine or amine derivative are heated together in an appropriate solvent to provide the corresponding 2-amino-6-chloro-3-nitropyridine (e), which is then coupled with an appropriately substituted acetylene to provide the corresponding 1,2-disubstituted acetylene (f). This acetylene is oxidized to provide the target diketone (a).
  • Compounds of Formula I where W is pyrazole (ii) or (iii) are prepared as described in the following Scheme where X, R, R , and R2 are as previously defined.
  • Figure US20090318443A1-20091224-C00014
  • Acetylene (f) is treated with mercuric oxide in aqueous sulfuric acid to provide the ketone (g). This ketone is treated with dimethylformamide dimethylacetal or tris(dimethyl-amino)methane in a suitable solvent, typically dimethylformamide, to provide the enaminoketone (h). The enaminoketone is then treated with hydrazine in a suitable solvent, typically ethanol or methanol, to provide the phenylpyrazole (j). The imidazo- or triazolopyridine moiety is prepared as previously described to provide the compounds of Formula Id.
  • The compounds of Formula I where W is the [1,2,3]triazole (iv) may be prepared as described in the following Scheme where variables Y, R, and R2 are as previously defined.
  • Figure US20090318443A1-20091224-C00015
  • The acetylene (f) is reacted with a source of azide, typically sodium azide, in a suitable solvent, such as dimethyoxyethane to provide the triazole (k). The imidazo- or triazolopyridine moiety is prepared as previously described to provide the compounds of Formula Ie.
  • The compounds of Formula I where W is the thiazole (v) or oxazole (vii) may be prepared as described in the following Scheme where variables X, R, R2, and R3 are as previously defined and Y is O or S.
  • Figure US20090318443A1-20091224-C00016
  • The α-bromoketone (I) is reacted with an appropriate amide (m, Y=O) or thioamide (m, Y=S) in a suitable solvent to provide the corresponding oxazole or thiazole (n). The oxazole (n, Y=O) is then treated with bromine in a suitable solvent to provide the corresponding brominated heterocycle (o, Y=O). The thiazole (n, Y=S) is treated with n-butyllithium and the resulting anion reacted with tributyltin chloride to provide the corresponding tin derivative (o, Y=S). The appropriately substituted heterocycle (o) is reacted with an appropriate boronic acid (p) in the presence of a suitable catalyst as previously described to provide the compounds of Formula If.
  • The requisite α-bromoketones are either commercially available or may be prepared by standard conditions from the corresponding carbonyl compound, for example, as described by House (H. O. House, Modern Synthetic Reactions, W. A. Benjamin, Inc., Menlo Park, Calif. (1972), pages 459-478) and Larock (R. C. Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, N.Y. (1989), pages 369-471, 755). The requisite amides and thioamides are either commercially available or may be prepared by standard methods well known to the skilled artisan.
  • Additional compounds of Formula I where W is imidazole (i) or isoxazole (vi) may be prepared under standard palladium coupling conditions as described in the following Scheme, where W′ is imidazole (i) or isoxazole (vi), and X and R are as previously defined.
  • Figure US20090318443A1-20091224-C00017
  • An appropriately substituted haloheteroaryl (q) is coupled with an appropriately substituted boronic acid (p) in the presence of a palladium catalyst, typically bis(triphenylphosphine)palladium(II) chloride, in a suitable solvent to provide the desired compound of Formula Ie. The requisite starting materials are either commercially available or may be prepared by methods well known to one of ordinary skill in the art.
  • Many of the compounds of the present invention are not only useful as inhibitors of p38 kinase, but are also useful intermediates for the preparation of additional compounds of the present invention. For example, primary and secondary amines may be acylated, alkylated or coupled with carboxylic acids or amino acids under standard peptide coupling conditions. Furthermore, ester moieties may be reduced to the corresponding alcohols or converted to amides under standard conditions. Alcohols may be activated and displaced by a number of nucleophilcs to provide other compounds of the invention. Such leaving groups include but are not limited to halides, oxonium ions, alkyl perchlorates, ammonioalkanesulfonate esters, alkyl fluorosulfonates, nonaflates, tresylates, triflates, and sulfonic esters, preferably the mesylate or tosylate. Techniques for the introduction of these groups are also well known to the skilled artisan; see, for example, March, Advanced Organic Chemistry, 5th Ed., John Wiley and Sons, New York, pg. 445-449 (2001). Additionally, the 2-amino moiety of the benzimidazole nucleus may be diazotized and displaced to provide additional compounds of the invention under standard conditions.
  • The skilled artisan will also appreciate that not all of the substituents in the compounds of Formula I will tolerate certain reaction conditions employed to synthesize the compounds. These moieties may be introduced at a convenient point in the synthesis, or may be protected and then deprotected as necessary or desired. The skilled artisan will appreciate that the protecting groups may be removed at any convenient point in the synthesis of the compounds of the present invention. Methods for introducing and removing nitrogen and oxygen protecting groups are well known in the art; see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons, New York, Chapter 7 (1999). Furthermore, the skilled artisan will appreciate that in many circumstances, the order in which moieties are introduced is not critical. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties.
  • The abbreviations, symbols and terms used in the examples and assays have the following meanings: AcOH=acetic acid; DMF=N,N-dimethylformamide; DMSO dimethylsulfoxide; Et2O=diethyl ether; EtOAc=ethyl acetate; EtOH=ethanol; h=hour(s); MeOH=methanol; min=minute(s); MTBE=methyl tert-butyl ether; Pd(OAc)2 =palladium acetate; RT =room temperature; THF=tetrahydrofuran; VO(acac)2=vanadyl acetylacetonate.
    • Preparation 1
  • [6-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3-nitropyridin-2-yl]-(2,2-dimethylpropyl)amine
    (6-Chloro-3 -nitropyridin-2-yl)-(2,2-dimethyl-propyl)amine
  • Add neopentylamine (18 mL, 150 mmol) to a suspension of 2,6-dichloro-3-nitropyridine (20 g, 103 mmol) and Na2CO3 (18.5 g, 175 mmol) in EtOH (1.6 mL/mmol) at RT and stir overnight. Concentrate and dilute the resultant slurry with water (100 mL) and slowly neutralize with concentrated HCl (approx. 40 mL) to pH=7. Cool the suspension at 0° C. for 1 h and collect solid by vacuum filtration. Wash the solid with ice water (4×50 mL) and air dry overnight. Recrystallize the material from EtOAc and hexanes to give the title compound as a yellow solid (21.23 g, 84%).
  • MS (ES): m/z=244 [M+H]
    (2.2-Dimethylpropyl)-(3-nitro-6-phenylethlynylpyridin-2-yl)amine
  • Dissolve (6-chloro-3-nitropyridin-2-yl)-(2,2-dimethylpropyl)amine (7.3 g, 30.0 mmol), phenylacetylene (5.0 mL, 45 mmol) and triphenylphosphine (1.5 mmol, 0.39 g) in triethylamine (10 mL/g) in an oven-dried round bottom flask is flushed with nitrogen and evacuated three times. Add Pd(OAc)2 (0.10 g, 0.45 mmol) and the nitrogen flush/evacuation cycle is repeated (3×). Heat at 70-80° C. with stirring under nitrogen for 1-3 h, then cool at RT for 2 h. Concentrate and partition between water (25 mL) and EtOAc (150 mL). Separate the organic layer and wash with water (4×25 mL), saturated aqueous NaCl (25 mL), dry with MgSO4, filter, and concentrate. Purify the crude solid by recrystallization from EtOAc/hexanes to give the title product as a bright orange solid (6.5 g, 21.2 mmol, 71%).
  • MS (ES): m/z=310 [M+H]; mp 90-92° C.
    1-[6-(2,2-Dimethylpropylamino)-5-nitropyridin-2-yl]-2-phenylethane-1,2-dione
  • Cool a mixture of (2,2-dimethylpropyl)-(3-nitro-6-phenylethynylpyridin-2-yl)amine (3.11 g, 10 mmol), NaHCO3 (0.420 g, 5.0 mmol), MgSO4 (2.40 g, 20 mmol) in acetone (85 mL), and water (25 mL) and cool to 0° C. Add KMnO4 (3.16 g, 20.0 mmol) to the cooled mixture, and stir the reaction mixture vigorously at 0° C. for about 1-2 h. Quench the mixture with Na2SO3 (5.67 g, 45 mmol). Remove ice bath and stir mixture at RT for 2 h. Filter the solid through a pad of filtering agent. Wash with water (2×50 mL) and EtOAc (50 mL). Separate the phases and extract the aqueous phase with EtOAc (3×50 mL). Wash the combined organic phases with saturated aqueous NaCl (25 mL), dry with MgSO4, filter and concentrate. Purify the crude (silica gel chromatography, eluting with 1:1 hexanes:CH2Cl2) to give the title compound (1.586 g, 46%).
  • MS (ES): m/z=342 [M+H]; mp 88-90° C.
    [6-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3 -nitropyridin-2-yl]-(2,2-dimethylpropyl)amine
  • Heat a mixture of 1-[6-(2,2-dimethylpropylamino)-5-nitropyridin-2-yl]-2-phenylethane-1,2-dione (1.0241 g, 3.0 mmol), trimethylacetaldehyde (0.66 mL, 6.0 mmol), ammonium acetate (3.47 g, 45 mmol) in AcOH (5 mL/mmol) at 80° C. with monitoring by liquid chromatography-mass spectroscopy for the appearance of product. Cool the reaction mixture to 0° C. and neutralize to pH 7 with 5.0 N NaOH. Extract the neutralized aqueous phase with EtOAc (3×20 mL) and wash the combined organic phases with 20 mL portions of saturated aqueous NaBCO3 until no further neutralization is observed. Dry the organic phase with MgSO4, filter, and concentrate. Triturate the orange crude solid with EtOAc to obtain the title compound (0.7578 g, 62%).
  • MS (ES): m/z=408 [M+H]; mp 224-226° C.
  • The compounds of Preparations 2-21 may be prepared essentially as described in Preparation 1.
  • MS (ES): m/z
    Prep. Compound [M + H]
    2 {6-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3- 464
    nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    3 {6-[2-(2,6-Dichlorophenyl)-5-phenyl-3H-imidazol-4-yl]-3- 496
    nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    4 {6-[2-(2-Chloro-6-fluorophenyl)-5-phenyl-3H-imidazol-4-yl]- 480
    3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    5 (2,2-Dimethylpropyl){6-[5-(4-fluorophenyl)-2-isopropyl-3H- 412
    imidazol-4-yl]-3-nitropyridin-2-ylamine
    6 Cyclopropylmethyl{6-[2-(2,6-difluorophenyl)-5-phenyl-3H- 448
    imidazol-4-yl]-3-nitropyridin-2-ylamine
    7 Cyclopropylmethyl{6-[2-(2,6-dichlorophenyl)-5-phenyl-3H- 480
    imidazol-4-yl]-3-nitropyridin-2-ylamine
    8 Cyclopropylmethyl{6-[2-(2,6-difluorophenyl)-5-(4- 466
    fluorophenyl)-3H-imidazol-4-yl]-3-nitropyridin-2-ylamine
    9 Cyclopropylmethyl{6-[2-(2,6-dichlorophenyl)-5-(4- 498
    fluorophenyl)-3H-imidazol-4-yl]-3-nitropyridin-2-ylamine
    10 Cyclopropylmethyl{6-[5-(4-fluorophenyl)-2-isopropyl-3H- 396
    imidazol-4-yl]-3-nitropyridin-2-ylamine
    11 [6-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3-nitropyridin-2- 392
    yl]cyclopropylmethylamine
    12 {6-[2-(2,6-Difluorophenyl)-5-(4-fluorophenyl)-3H-imidazol-4- 482
    yl]-3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    13 {6-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3- 410
    nitropyridin-2-yl}cyclopropylmethylamine
    14 [6-(2-Cyclopropyl-5-phenyl-3H-imidazol-4-yl)-3-nitropyridin- 392
    2-yl]-(2,2-dimethylpropyl)amine
    15 (2,2-Dimethylpropyl)-{6-[5-(4-fluorophenyl)-2-(2-fluoro-6- 532
    trifluoromethylphenyl)-3H-imidazol-4-yl]-3-nitropyridin-2-
    ylamine
    16 (2,2-Dimethylpropyl)-{6-[2-(2-fluoro-6- 514
    trifluoromethylphenyl)-5-phenyl-3H-imidazol-4-yl]-3-
    nitropyridin-2-ylamine
    17 {6-[2-Cyclopropyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3- 410
    nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    18 {6-[2-(2,6-Dichlorophenyl)-5-(4-fluorophenyl)-3H-imidazol- 514
    4-yl]-3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    19 {6-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3- 426
    nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    20 {6-[2-tert-Butyl-5-(2,4-difluorophenyl)-3H-imidazol-4-yl]-3- 444
    nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    21 {6-[5-(2,4-Difluorophenyl)-2-(2,6-difluorophenyl)-3H- 500
    imidazol-4-yl]-3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine
    • Preparation 22
  • 6-[2-(2,6-Dichlorophenyl)-5-phenyl-1H-imidazol-4-yl]-N2-isobutylpyridine-2,3-diamine
  • Add sodium dithionite (2.58 g, 14.82 mmol) followed by 32% NH4OH (9 mL) to a solution of {6-[2-(2,6-dichlorophenyl)-5-phenyl-1H-imidazol-4-yl]-3-nitropyridin-2-yl} isobutylamine (1.43 g, 2.96 mmol) in 50 mL of 1:1 THF:water mixture. Stir the mixture at RT for 2 h. Dilute with EtOAc. Wash the organic layer with saturated aqueous NaCl and dry the organic phase over Na2SO4. Concentrate to yield the title compound (1.32 g, 98%).
    • Preparation 23
  • 2-Isobutylamino-3-nitro-6-[3-(4-fluorophenyl)-1-morpholinoethylpyrazol-4-yl]pyridine
    2-Isobutylamino-3-nitro-6-(4-fluorophenylethanone)pyridine
  • Add an aqueous suspension of HgO (0.55 g, 2.54 mmol) in 100 mL of 4% H2SO4 to a solution of 2-isobutylamino-3-nitro-6-(4-fluorophenyl)ethynylpyridine (3.99 g, 12.7 mmol) in 100 mL of MeOH. Stir at 95 ° C. for 17 h and cool to RT. Filter the mixture through a filtering agent and dissolve the precipitate with EtOAc (5×100 mL). Concentrate and wash the residue with 10:2:1 hexane:diethyl ether:MeOH (130 mL) to provide the title compound (2.60 g, 62%).
  • MS (ES): m/z=332 [M+H].
    2-Isobutylamino-3-nitro-6-[3-(4-fluorophenyl)pyrazol-4-yl]pyridine.
  • Add dimethylformamide dimethyl acetal (4.50 mL, 33.8 mmol) to a stirred solution of 2-isobutylamino-3-nitro-6-(4-fluorophenyl-ethanone)-pyridine (5.63 g, 16.1 mmol) in 15 mL of dry DMF. Heat the mixture at 80° C. for 6 h, cool to RT and concentrate. Dissolve the residue in 100 mL of EtOH, add 8.30 mL of hydrazine (80% in H2O), stir for 2 h and concentrate. Purify the residue (silica gel chromatography, eluting with hexanes:EtOAc 1:1) to give the title compound (4.51 g, 75%).
  • MS (ES): m/z=356 [M+H].
    2-Isobutylamino-3-nitro-6-[3-(4-fluorophenyl)-1-morpholinoethylpyrazol-4-yl]pyridine
  • Treat a solution of 2-isobutylamino-3-nitro-6-[3-(4-fluorophenyl)pyrazol-4-yl]pyridine (1.25 g, 3.52 mmol) in dry DMF (15 mL) with 95% NaH (0.36 g, 14.3 mmol) at 0° C. for 15 min. Add morpholinoethylchloride hydrochloride (0.983 g, 5.28 mmol) and slowly warm to RT. Add additional NaH (0.36 g, 14.3 mmol), after 1 h and stir the reaction mixture for 24 h. Quench with MeOH (1 mL) and dilute with water (30 mL). Extract with EtOAc (100 mL), dry with MgSO4, and concentrate. Purify the residue (silica gel chromatography, eluting with hexanes:EtOAc 1:2) to give the title compound (1.35 g, 81%).
  • MS (ES): m/z=b 469 [M+H].
    • Preparation 24
  • (2,2-Dimethylpropyl)-[3 -nitro-6-(5-phenyl-3H-[1,2,3]triazol-4-yl)-pyridin-2-yl]amine
  • Add sodium azide (0.065 g) to a solution of 2,2-dimethylpropyl-(2-nitro-5-phenylethynylphenyl)amine (0.153 g) in of DMSO (2.5 mL). Heat at 80° C. for 2 h. Cool to RT. Add 10 mL of 1N HCl and extract with EtOAc (20 mL) and wash with saturated aqueous NaCl (2×10 mL). Dry the remaining organic phase over Na2SO4 and concentrate. Purify the residue (silica gel chromatography, eluting with EtOAc:hexanes 1:2) to give the title compound as yellow solid (0.176 g, 100%).
  • MS (ES): m/z=353 [M+H].
    • Preparation 25
  • 2-Amino-5-(2-oxo-2-phenylacetyl)imidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide
    N,N-dimethyl-N′-(6-chloro-3-nitropyridin-2-yl)sulfonic acid
  • Stir a mixture of 2,6-dichloro-3-nitropyridine (1 g, 2.60 mmol) and N,N-dimethylsulfamide (0.78 g, 3.12 mmol) in dry DMF (5 mL). Add lithium hydride (0.11 g, 6.76 mmol) and stir at RT overnight. Add 10 mL of water and 3N HCl until pH=7. Filter the yellow solid to provide the title compound (85%).
  • MS (ES): m/z=279 [M+H].
    N,N-dimethyl-N′-(3-nitro-6-phenylethnylpyridin-2-yl)sulfonic acid
  • Bubble nitrogen through a mixture of N,N-dimethyl-N′-(6-chloro-3-nitropyridin-2-yl)sulfonic acid (3.86 g, 13.7 mmol), phenylacetylene (2.3 mL, 20.67 mmol), triphenylphosphine (0.09 g, 0.68 mmol) and copper (I) iodide (0.06 g, 0.34 mmol) in triethylamine (30 mL) and THF (60 mL) for 3 min. Add bis(triphenylphosphine)palladium (II) chloride (0.24 g, 0.34 mmol) to the mixture and heat at 110° C. for 4 h. Filter through a pad of filtering agent and concentrate. Purify the residue (silica gel chromatography, eluting with 1:1 hexanes:EtOAc) to give the title compound (80%).
  • MS (ES): m/z=346 [M+H].
    N,N-dimethyl-N′-(3-amino-6-phenylethynylpyridin-2-yl)sulfonic acid
  • Stir a mixture of N,N-dimethyl-N′-(3-nitro-6-phenylethynylpyridin-2-yl)sulfonic acid (0.09 g, 0.26 mmol) and tin chloride dihydrate (0.35 g, 1.56 mmol) in EtOAc (5 mL) and EtOH (2.5 mL) at 70° C. for 2 h. Concentrate and purify the residue (silica gel chromatography, eluting with 1:1 hexanes:EtOAc) to give the title compound (65%).
  • MS (ES): m/z=317 [M+H].
    2-Amino-5-phenylethynylimidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide
  • Stir a mixture of N,N-dimethyl-N′-(3-amino-6-phenylethynylpyridin-2-yl)sulfonic acid (0.20 g, 0.63 mmol), cyanogen bromide (0.07 g, 0.69 mmol) and lithium methoxide (0.04 g, 0.94 mmol) in 1,2 diclhloroethane (20 mL) at 80° C. overnight. Concentrate and purify the residue (silica get chromatography, eluting with 1:1 hexanes:EtOAc) to give the title compound (45%).
  • MS (ES): m/z=342 [M+H].
    2-Amino-5-(2-oxo-2-phenylacetyl)imidazo[4.5-b]pyridine-3-sulfonic acid dimethylamide
  • Add a solution of 2-amino-5-phenylethynylimidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide (0.10 g, 0.31 mmol) in acetone (4 mL) over a mechanically stirred solution of NaHCO3 (0.01 g, 0.15 mmol) and MgSO4 (0.07 g, 0.62 mmol) in water (4 mL) at 0° C.
  • Add KMnO4 (0.12 g, 0.748 mmol) and stir at 0° C. overnight. Add Na2SO3 (0.13 g), and stir for 1 h. Add EtOAc and wash with a saturated aqueous solution of NaCl, and concentrate to give the title compound as an orange solid which is used without further purification (68% yield).
  • MS (ES): m/z=372 [M+H].
    • Preparation 26
  • Propane-2-sulfonic acid {3-amino-6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]pyridin-2-yl } amide
    Propane-2-sulfonic acid (3-nitro-6-phenylethynylpyridin-2-yl)amide
  • Add propane-2-sulfonic acid (5-chloro-2-nitrophenyl)amide (10 g, 35.7 mmol), phenylacetylene (5.9 mL, 53.6mmol) and triphenylphosphine (0.46 g, 1.78 mmol) to a solution of triethylamine (25 mL, 178.5 mmol) in dry THF (25 mL) and flush the system with nitrogen. Add dichlorobis(triphenylphosphine)palladium(II) (0.625 g, 0.89 mmol) and copper (I) iodide (0.17 g, 0.89 mmol) to this stirring mixture. Heat the reaction to reflux for 4 h. Cool to RT and concentrate to a slurry. Filter the crude material through a plug of silica gel using EtOAc as the eluting solvent. Concentrate the filtrate and crystallize the title compound from EtOAc-hexanes (7.9 g, 64%).
  • MS (ES): m/z=346 [M+H].
    Propane-2-sulfonic acid [3-nitro-6-(2-oxo-2-phenylacetyl)pyridin-2-yl]amide
  • Heat a mixture of propane-2-sulfonic acid (3-nitro-6-phenylethynylpyridin-2-yl)amide (1.8 g, 5.26 mmol) and palladium (II) chloride (0.93 g, 0.53 mmol) in dry DMSO (20 mL) at 120° C. for 12 h under a nitrogen atmosphere. Cool to RT, concentrate to a slurry, and purify (silica gel chromatography, eluting with a gradient of 20:80 EtOAc:hexanes to 30:70 EtOAc:hexanes) to give the title compound (1.07 g, 54%).
  • MS (ES): m/z=346 [M+H].
    Propane-2-sulfonic acid {6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitropyridin-2-yl} amide
  • Heat a mixture of propane-2-sulfonic acid [3-nitro-6-(2-oxo-2-phenylacetyl)pyridin-2-yl]amide(0.25 g, 0.67 mmol), 2,6-difluorobenzaldehyde (0.146 mL, 1.35mmol) and ammonium acetate (0.78 g, 10.05 mmol) in AcOH (5 mL) at 110° C. for 2 h. Cool to RT and concentrate. Dilute with EtOAc (30 mL), extract successively with saturated NaHCO3 and saturated aqueous NaCl. Dry the organic layer over NaSO4, concentrate, and purify (silica gel chromatography, eluting with 30:70 EtOAc:hexanes) to give the title compound (0.32 g, 95%).
  • MS (ES): m/z=500 [M+H].
    Propane-2-sulfonic acid {3-amino-6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-pyridin-2-yl } amide
  • Add 10% Pd/C (0.033 g) to a stirring solution of propane-2-sulfonic acid {6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitropyrdin-2-yl} amide (0.33 g, 0.66 mmol) in MeOH (10 mL). Add sodium borohydride (0.124 g, 3.3 mmol) in portions and with stirring under nitrogen for 15 min. Filter the catalyst and concentrate. Dilute with EtOAc (20 mL) and extract successively with saturated NaHCO3 and saturated aqueous NaCl. Dry the organic layer over Na2SO4 and concentrate to give the title compound (0.3 g, 98%).
  • MS (ES): m/z=470 [M+H].
    • Preparation 27
  • Propane-2-sulfonic acid {3-amino-6-[2-(2,6-diclhlorophenyl)-5-phenyl-3H-imidazol-4-yl]-pyridin-2-yl} amide
  • Heat a mixture of propane-2-sulfonic acid {6-[2-(2,6-dichlorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitropyridin-2-yl} amide (0.262 g, 0.49 mmol) and tin (II) chloride dihydrate (0.55 g, 2.46 mmol) in EtOH (10 mL) at 100° C. for 1 h. Cool to RT and concentrate to a slurry. Pour the reaction mixture into saturated NaHCO3 (20 mL) and add a filtering agent. Filter and wash with EtOAc. Separate the layers and extract successively with saturated NaHCO3 and saturated aqueous NaCl. Dry the organic layer over Na)SO4 and concentrate to give the title compound (0.21 g, 85%).
  • MS (ES): m/z=504 [M+B].
    • Preparation 28
  • 1-Benzyl-2-methyl-4-bromo-5-(2,4-difluorophenyl)-1H-imidazole 1-Benzyl-2-methyl-5-bromo-1H-imidazole
  • Add N-bromosuccinimide (7.85 g, 44 mmol) to a solution of 1-benzyl-2-methyl-1H-imidazole (8.0 g, 46 mmol) in chloroform (200 ml.) and stir for 6 h. Wash with saturated aqueous sodium hydrogen carbonate and saturated aqueous NaCl, dry over MgSO4, and filter through a pad of silica gel. Concentrate filtrate and suspend the residue in diethyl ether (600 mL), heat to reflux, and filter hot. Concentrate ether filtrate to give the title compound as a tan solid (9.3 g).
  • MS (ES): m/z=252 [M+H].
    1-Benzyl-2-methyl-5-(2,4-difluorophenyl)-1H-imidazole
  • Heat a mixture of 1-benzyl-2-methyl-5-bromo-1H-imidazole (4.71 g, 18.7 mmol), 2,4-difluorophenyl boronic acid (6.92 g, 43.8 mmol), bis(acetato)bis(triphenylphosphine)-palladium(II) (1.4 g, 1.875 mmol), 2N Na2CO3 (19 mL, 38 mmol), MeOH (19 mL) and 1,2-dimethoxyethane (120 mL) to reflux for 18 h. Cool to RT. Add water and EtOAc and separate the layers. Dry organic layer over MgSO4, filter, and concentrate. Purify the residue (silica gel chromatography, eluting with EtOAc:CH2Cl2 mixtures) to give the desired compound (3.59 g).
  • MS (ES): m/z=285 [M+H].
    • Bromination
  • Stir a mixture of 1-benzyl-2-methyl-5-(2,4-difluorophenyl)-1H-imidazole (3.58 g, 12.6 mmol) and N-bromosuccinimide (2.24 g, 12.6 mmol) in chloroform (100 mL) at RT for 18 h. Add the reaction mixture directly onto silica gel and elute with CH2Cl2:EtOAc mixtures to give title compound (3.41 g).
  • MS (ES): m/z=364 [M+H].
    • Preparation 29
  • 2-tert-Butyl-4-(4-fluorophenyl)oxazole
  • Reflux a solution of commercially available 2-bromo-4′-fluoroacetophenone (100.00 g, 460 mmol), 2,2-dimethyl-propioiiamide (93.06 g, 20 mmol) in 1,4-dioxane (600 mL) for 2 days. Filter precipitate, concentrate filtrate, and purify (silica gel chromatography, eluting with hexanes:EtOAc 60:1) to give the title compound (55 g, 55%).
  • MS (ES): m/z=220 [M+H].
  • The compounds of Preparations 30-31 may be prepared essentially as described in Preparation 29.
  • MS (ES): m/z
    Prep. Compound [M + H]
    30 2-tert-Butyl-4-(2,4-difluorophenyl)oxazole 238
    31 4-(4-Fluorophenyl)-2-isopropyloxazole 206
    • Preparation 32
  • 2-tert-Butyl-4-(4-fluorophenyl)-5-trimethylstannanyloxazole
  • Dissolve 2-tert-butyl-4-(4-fluorophenyl)oxazole (0.61 g, 2.77 mmol) in THF (15 ml) and add tert-butyl lithium (3.3 ml, 1.7 M) at −78° C. Stir the mixture for 45 min. Add trimethylstannanyl chloride (0.58 g, 2.90 mmol) and allow the temperature to reach RT. Stir for 2 h and add an ammonium chloride solution (200 μL, pH=8 with ammonia) and concentrate.
    • 1H NMR (CDCl3) δ 7.46 (m. 2H), 6.95 (m, 2H), 1.32 (s, 9H), 0.24 (s, 9H). Preparation 33
  • 4-(4-Fluorophenyl)-2-methylthiazole
  • Reflux a solution of 2-bromo-4′-fluoroacetophenone (10 g, 46 mmol) and thioacetamide (6.9 g, 92 minol) in 1,4-dioxane (60 mL) for 3 h. Filter the precipitate and wash with EtOAc to give the title compound (6.5 g, 73%).
  • MS (ES): m/z=194 [M+H].
  • The compound of Preparation 34 may be prepared essentially as described in Preparation 33.
  • MS (ES): m/z
    Prep. Compound [M + H]
    34 2-Methyl-4-phenylthiazole 176
    • Preparation 35
  • 2-Amino-5-bromoimidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide 2,6-Dibromo-3 -nitropyl2idine
  • Heat at 50° C. a mixture of 2,6-dichloro-3-nitropyridine (9 g) and hydrobromic acid (90 mL) in AcOH (30%) overnight . Cool to RT and pour into water (600 mL). Filter the solid to provide the title compound (87%).
    • 1H NMR (CDCl3) δ 7.93(d, J=8.14 Hz, 1H), 7.55 (d, J=8.14 Hz, 1H).
  • N,N-Dimethyl-N′-(6-bromo-3-nitropyridin-2-yl)sulfonic acid
  • Stir a mixture of 2,6-dibromo-3-nitropyridine (11.3g, 39.25 mmol) and N, N-dimethylsulfamide (0.006 g, 47.10 mmol) in DMF (40 mL). Add lithium hydride (0.81 g, 102.05 mmol) and stir at RT overnight. Add 100 mL of water and 3 N HCl until pH=7.
  • Filter the yellow solid to provide the title compound (93%).
    • 1H NMR (DMSO-d6) δ 10.25 (br s, 1H), 8.41(d, J=8.59 Hz, 1H), 7.50 (d, J=8.59 Hz, 1H), 2.95 (2, 6H).
  • N,N-dimethyl-N′-(3-amino-6-bromo-)pyridin-2-yl)-sulfonic acid
  • Heat a mixture of N,N-dimethyl-N′-(6-bromo-3-nitropyridin-2-yl)sulfonic acid (11.6 g, 35.69 mmol) and tin chloride (40 g, 178 mmol) in EtOAC:EtOH 500:250 mL for 4 h. Concentrate and purify the residue (silica gel chromatography, eluting with 1:1 hexane:EtOAc). Triturate with water to provide the title compound (85%).
  • MS (ES): m/z=297 [M+H].
    2-Amino-5-bromoimidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide
  • Stir a mixture of N,N-dimethyl-N′-(3-amino-6-bromopyridin-2-yl)sulfonic acid (0.40 g, 1.35 mmol), cyanogen bromide (0.08 g, 1.48 mmol) and lithium methoxide (0.08 g, 2.02 mmol) in 1,2-dichloroethane (400 mL). Stir at 80° C. for 2 h. Concentrate and purify the residue (silica gel chromatography, eluting with 1:1 hexane:EtOAc) to give the title compound (82%).
  • MS (ES): m/z=322 [M+H].
    • Preparation 36
  • 1-[2-amino-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-(2,4-difluoro-phenyl)-ethane-1,2-dione
    5-(2,4-difluoro-phenylethynyl)-3-(2.2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine
  • Combine 5-bromo-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (30.00 g, 105.94 mmol), Et3N (60 mL), and Pd(OAc)2[P(Ph)3]2 (3.97 g, 5.30 mmol) in toluene (150 mL) and heat the resulting mixture to −65° C. under nitrogen. Add 1-ethynyl-2,4-difluoro-benzene (21.95 g, 158.92 mmol) in toluene (30 mL) dropwise to the above mixture, and then heat the resulting reaction mixture at 80° C. for 3 h. Cool the reaction to 25° C. and quench with saturated aqueous NH4Cl (300 mL). Stir the resulting reaction mixture at room temperature for 20 minutes, then filter, washing the solid with H2O and drying under vacuum filtration for 30 minutes. Slurry the solid in MTBE (200 mL), then filter and rinse with MTBE (50 mL). Dry the recovered solid under vacuum filtration to provide 14.47 g of the title compound as a light-yellow solid.
  • MS(ES+): m/z=341 (M+1)
    • Oxidation
  • Treat a solution of 5-(2,4-difluoro-phenylethynyl)-3-(2,2-)dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (14.47 g, 42.51 mmol) in acetone (350 mL) with a solution of MgSO4 (10.23 g, 85.00 mmol) and NaHCO3 (1.79 g, 21.30 mmol) in water (200 mL). Place the resulting reaction mixture in a H2O bath. Add celite (28.50 g), followed by KMnO4 (14.11 g, 89.28 mmol) over 10 minutes, as the reaction exotherms to ˜30° C. Stir at room temperature for 3 h, then quench with 10 wt % of aqueous Na2SO3 (150 mL). Stir for 30 minutes, then filter over a pad of celite, washing with 10% MeOH/EtOAc (2×700 mL each). Separate the layers of the filtrate and extract the aqueous with EtOAc (2×500 mL each). Wash the combined organics with H2O (500 mL) and saturated aqueous sodium chloride (500 mL), then dry over Na2SO4, filter, and concentrate under reduced pressure to afford a solid. Wash the filter pad of celite with 10% MeOHIEtOAc and concentrate the filtrate under reduced pressure to obtain additional solid. Combine the solids and purify by column chromatography, eluting with 2% of 2N NH4/MeOH in EtOAc, then 5% of 2N NH4)MeOH in EtOAc to give 13.08 g (82% yield) of the title compound as an orange-brown solid.
  • MS(ES+): m/z=373 (M+1)
    • Preparation 37
  • {6-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(1 (R),2,2-trimethyl-propyl)-amine
    1 -[6-(1((R), 22-trimethylpropylamino)-5-nitropyridin-2-yl]-2-((4-fluorophenyl)ethane-1,2-dione
  • Dissolve [6-(4-fluoro-phenylethynyl)-3 -nitro-pyridin-2-yl]-(1 (R),2,2-trimethyl-propyl)-amine (2.73 g, 8.00 mmol) in acetone (60 mL). Add water (20 mL), then NaHCO3 (336 mg, 4 mmol, 0.5 equiv), and MgSO4 (1.9 g, 16 mmol, 2.0 equiv) and chill the reaction to about 3° C. Add KMnO4 (2.5 g, 16 mmol, 2.0 equiv) portionwise with vigorous stiffing while maintaining the temperature below 3° C. Quench the reaction after 1-2 h by adding water (20 mL) and Na2SO3 (4.5 g, 36 mmol) and stirring the mixture at ambient temperature for 1 h. Filter the suspension over Celite® with the aid of 600 mL ethyl acetate and about 300 mL water. Separate the layers and wash the organic layer four times with saturated aqueous NaHCO3 and twice with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter off the solids, and concentrate the supernatant under reduced pressure. Subject the residue to medium pressure silica gel chromatography eluting with a 50-70% gradient of CH2Cl2 in hexaines to give the desired compound as an orange oil (1.82 g, 61% yield).
  • MS(ESI): m/z=374.1 (M+H)+.
    • Ring Formation
  • Dissolve 1-[6-(1 (R),2,2-trimethylpropylamino)-5-nitropyridin-2-yl]-2-((4-fluorophenyl)ethane-1,2-dione (747 mg, 2.0 mmol) in glacial acetic acid (10 mL), add ammonium acetate (2.3 g, 30 mmol, 15 equiv), and then add trimethylacetaldehyde (344 mg, 4.0 mmol, 2 equiv). Heat the reaction mixture to 100° C. for 1 h and concentrate under reduced pressure. Partition the resulting solids between ethyl acetate and water. Wash the organic layer 5 times with saturated aqueous NaHCO3, and twice with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter, and concentrate under reduced pressure. Subject the residue to medium pressure silica gel chromatography eluting with an isocratic 10% ethyl acetate/hexanes system to give the title compound as an orange solid. (589 mg, 67% yield)
  • MS(ESI): m/z=440.2 (M+H)+
  • The compounds of Preparations 38-40 may be prepared essentially as described in Preparation 37.
  • MS (ESI): m/z
    Prep. Compound [M + H]
    38 {6-[2-(2,6-difluorophenyl)-5-(4-fluoro-phenyl)- 496.1
    3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-
    (1(R),2,2-trimethyl-propyl)-amine
    39 {6-[2-(2-fluoro-6-trifluoromethylphenyl)-5-(4- 546.2
    fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-
    2-yl}-(1(R),2,2-trimethyl-propyl)-amine
    40 {6-[2-(2-chloro-6-fluorophenyl)-5-(4-fluoro- 512.2
    phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-
    yl}-(1(R),2,2-trimethyl-propyl)-amine
    • Preparation 41
  • {6-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(2,2-dimethyl-propyl)-amine
  • Dissolve 1-(4-fluoro-phenyl)-2-[5-nitro-6-(2,2-dimethylpropylamino)-pyridin-2-yl]-ethane-1,2-dione (1.08 g, 3.0 mmol) in glacial acetic acid, add ammonium acetate (3.47 g, 45 mmol, 15 equiv), and then add trimethylacetaldehyde (517 mg, 6.0 mmol, 2 equiv). Heat the reaction mixture to 100° C. for 1 h and concentrate under reduced pressure. Partition the resulting solids between ethyl acetate and water. Add NaHCO3 until gas evolution ceases. Wash the organic layer 5 times with saturated aqueous NaHCO3 and once with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter, and concentrate under reduced pressure to give the title compound as a yellow-orange solid. (1.25 g, 97% yield)
  • Exact MS: calc.: m/z=426.230 (M+H)+; found: m/z=426.2313 (M+H)+.
    • EXAMPLE 1
  • 5-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Stir a suspension of 6-(2-tert-butyl-5-phenyl-3H-imidazol-4-yl)-3-nitropyridin-2-yl]-(2,2-dimethylpropyl)amine (0.20 g, 0.5 mmol) and 10% palladium on carbon (0.025 g) in EtOH (10 mL) under a balloon of hydrogen overnight. Filter the suspension through a filtering agent and wash with EtOH (2×5 mL). Concentrate the filtrate to about 5 mL, and treat at RT with cyanogen bromide (1.3 mmol). Quench with saturated aqueous sodium bicarbonate (2 mL) and stir for 15-60 min. Dilute the mixture with water (5 mL) and extract with CH2Cl2 (2×10 mL). Wash the combined organic phases with saturated aqueous NaCl (5 mL), dry with MgSO4, filter, concentrate, and purify (silica gel chromatography, eluting with a step gradient beginning with 100% CH2Cl2, to 5:95 ammoniated MeOH:CH2Cl2) to give the desired compound. The free base is isolated and then converted to the methanesulfonate salt by treatment of a MeOH-water solution with methanesulfonic acid followed by lyophilization to give the title compound.
  • MS (ES): m/z=402 [M+H].
  • The compounds of EXAMPLES 2-14 may be prepared essentially as described in 2 0 EXAMPLE 1.
  • MS (ES):
    EXAMPLE Compound m/z [M + H]
    2 5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]- 459
    3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    3 5-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3- 387
    cyclopropylmethyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    4 5-(2-Cyclopropyl-5-phenyl-3H-imidazol-4-yl)-3-(2,2- 387
    dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    5 3-(2,2-Dimethylpropyl)-5-[5-(4-fluorophenyl)-2-(2- 527
    fluoro-6-trifluoromethylphenyl)-3H-imidazol-4-yl]-3H-
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    6 3-(2,2-Dimethylpropyl)-5-[2-(2-fluoro-6- 509
    trifluoromethylphenyl)-5-phenyl-3H-imidazol-4-yl]-
    3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    7 5-[2-Cyclopropyl-5-(4-fluorophenyl)-3H-imidazol-4- 405
    yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-
    2-ylamine methanesulfonate
    8 5-[2-(2,6-Difluorophenyl)-5-(4-fluorophenyl)-3H- 477
    imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    9 5-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3- 421
    (2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    10 5-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3- 405
    cyclopropylmethyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    11 5-[2-tert-Butyl-5-(2,4-difluorophenyl)-3H-imidazol-4- 439
    yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-
    2-ylamine methanesulfonate
    12 R-5-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4- 435
    yl]-3-(1,2,2-trimethylpropyl)-3H-imidazol[4,5-
    b]pyridin-2-ylamine methanesulfonate
    13 R-5-[2-(2,6-Difluorophenyl)-5-(4-fluorophenyl)-3H- 491
    imidazol-4-yl]-3-(1,2,2-trimethylpropyl)-3H-
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    14 R-5-[5-(4-Fluorophenyl)-2-(2-fluoro-6-trifluoromethyl- 541
    phenyl)-3H-imidazol-4-yl]-3-(1,2,2-trimethylpropyl)-
    3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    • EXAMPLE 15
  • 3-Cyclopropylmethyl-5-[2-(2,6-dichlorophenyl)-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Treat a suspension of (cyclopropylmethyl{6-[2-(2,6-dichlorophelyl)-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3-nitropyridin-2-yl}amine (0.250 g, 0.5 mmol) in EtOH (10 mL) with tin dichloride dihydrate (0.5641 g, 2.5 mmol) and heat at reflux for 2.5 h under nitrogen. Cool to RT and quench slowly with saturated aqueous NaHCO3 (5 mL) and EtOAc (5 mL). Add filtering agent to the resulting suspension and dilute the mixture further with 5 mL each of aqueous NaHCO3 and EtOAc. Filter the mixture through a pad of the filtering agent. Wash the solid with 10 mL each of aqueous NaHCO3 and EtOAc. Separate the layers and extract the aqueous phase with EtOAc (10 mL). Wash the combined organic phases with saturated aqueous NaCl (5 mL), dry with MgSO4, filter and concentrate. Dissolve the crude phenylenediamine in EtOH (5 mL) and treat with cyanogen bromide (1.0 mmol). Quench with saturated aqueous NaHCO3 (2 mL) and stir for 15-60 min. Dilute mixture with water (5 mL) and extract with CH2Cl2 (2×10 mL). Wash the combined organic phases with saturated aqueous NaCl (5 mL), dry with MgSO4, filter, concentrate, and purify (silica gel chromatography, eluting with a step gradient beginning with 100% CH2Cl2 to 5:95 5% ammonia in MeOH:CH2Cl2 to give the desired compound. Isolate the free base and convert it to the methanesulfonate salt by treatment of a MeOH-water solution with methanesulfonic acid followed by lyophilization.
  • MS (ES): m/z=495.1 [M+H].
  • The compounds of EXAMPLES 16-35 may be prepared essentially as described in EXAMPLE 15.
  • MS (ES):
    EXAMPLE Compound m/z [M + H])
    16 3-Cyclopropylmethyl-5-[2-(2,6-difluorophenyl)-5-(4- 461
    fluorophenyl)-3H-imidazol-4-yl]-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    17 5-[2-(2,6-Dichlorophenyl)-5-(4-fluorophenyl)-3H- 509
    imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    18 5-[2-(2-Chloro-6-fluorophenyl)-5-phenyl-3H-imidazol- 475
    4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    19 3-Cyclopropylmethyl-5-[2-(2,6-difluorophenyl)-5- 443
    phenyl-3H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    20 3-Cyclopropylmethyl-5-[2-(2,6-dichlorophenyl)-5- 476
    phenyl-3H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    21 5-[5-(2,4-Difluorophenyl)-2-(2,6-difluorophenyl)-3H- 495
    imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    22 5-[3-(4-Fluorophenyl)-1-methylpyrazol-4-yl]-3H-3- 365
    isobutyl-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    23 5-[5-(4-Fluorophenyl)-1-methylpyrazol-4-yl]-3H-3- 365
    isobutyl-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    24 5-[3-(4-Fluorophenyl)-1-morpholinoethylpyrazol-4-yl]- 464
    3H-3-isobutyl-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    25 5-[3-(4-Fluorophenyl)-pyrazol-4-yl]-3H-3-isobutyl- 351
    imidazo[4,5-b]pyridin-2-ylamine di-methanesulfonate
    26 3H-3-isobutyl-5-(3-phenyl-1-isopropylpyrazol-4-yl)- 375
    imidazo[4,5-b]pyridin-2-ylamine di-methanesulfonate
    27 3H-3-isobutyl-5-(3-phenyl-1-methylpyrazol-4-yl)- 347
    imidazo[4,5-b]pyridin-2-ylamine di-methanesulfonate
    28 3H-3-isobutyl-5-(3-phenyl-pyrazol-4-yl)-imidazo[4,5- 333
    b]pyridin-2-ylamine di-methanesulfonate
    29 5-[3-(2,4-Difluorophenyl)pyrazol-4-yl]-3H-3-isobutyl- 369
    imidazo[4,5-b]pyridin-2-ylamine di-methanesulfonate
    30 5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]- 445
    3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    31 5-[2-(2,6-Dichlorophenyl)-5-phenyl-3H-imidazol-4-yl]- 491
    3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    32 5-[2-(2,6-Dichlorophenyl)-5-phenyl-1H-imidazol-4-yl]- 477
    3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    33 5-[2-(2,6-Dichlorophenyl)-5-(4-fluorophenyl)-1H- 495
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    34 5-[2-(2,6-Dichlorophenyl)-5-(2,4-difluorophenyl)-1H- 513
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    35 R-5-[2-(2-Chloro-6-fluorophenyl)-5-(4-fluorophenyl)- 507
    3H-imidazol-4-yl]-3-(1,2,2-trimethylpropyl)-3H-
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    • EXAMPLE 36
  • 5-[2-tert-Butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]1-3-(2,2-dimethylpropyl)-2-methyl-3H-imidazo[4,5-b]pyridine methanesulfonate
  • Reduce and isolate {6-[2-tert-butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine (0.43 g; 1.0 mmol) as in EXAMPLE 1. React the crude diamine with neat triethylorthoacetate at 120° C. overnight. Concentrate and dilute with 15 mL 1N HCl. Neutralize with saturated NaHCO3 and extract with CH2Cl. Wash the organic layer with saturated NaCl, dry with Na2SO4, concentrate, and purify (silica gel chromataography, eluting with EtOAc:CH2Cl2 50:50) to give the title compound as a tan solid (0.11 g; 53% yield). The free base product is converted to the methanesulfonate salt essentially as described in EXAMPLE 1.
  • MS (ES): m/z=420 [M+H].
  • The compounds of EXAMPLES 37-38 may be prepared essentially as described in EXAMPLE 36.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H]
    37 5-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3-(2,2- 402
    dimethyl-propyl)-2-methyl-3H-imidazo[4,5-
    b]pyridine methanesulfonate
    38 5-[2-(2-Chloro-6-fluorophenyl)-5-phenyl- 474
    3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-2-methyl-
    3H-imidazo[4,5-b]pyridine methanesulfonate
    • EXAMPLE 39
  • 5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3 -(2,2-dimethylpropyl)-2-methyl-3H-imidazo[4,5-b]pyridine methanesulfonate
  • Reduce {6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitropyridini-2-yl}-(2,2-dimethylpropyl)amine essentially as described in EXAMPLE 16, and then react the diamine in trimethylorthoacatate as described in EXAMPLE 36 to give the free base as a tan solid (0.11 g; 49% yield). The methanesulfonate of the free base is formed essentially as described in EXAMPLE 1.
  • MS (ES): m/z=458 [M+H].
  • The compounds of EXAMPLES 40-45 may be prepared essentially as described in EXAMPLE 39.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H]
    40 5-[2-(2,6-Difluorophenyl)-5-(4-fluorophenyl)-3H- 476
    imidazol-4-yl]-3-(2,2-dimethylpropyl)-2-methyl-3H-
    imidazo[4,5-b]pyridine methanesulfonate
    41 5-[2-(2,6-Dichlorophenyl)-5-(4-fluorophenyl)-3H- 508
    imidazol-4-yl]-3-(2,2-dimethylpropyl)-2-methyl-3H-
    imidazo[4,5-b]pyridine methanesulfonate
    42 3-Cyclopropylmethyl-5-[2-(2,6-difluorophenyl)-5- 442
    phenyl-3H-imidazol-4-yl]-2-methyl-3H-imidazo[4,5-
    b]pyridine methanesulfonate
    43 3-Cyclopropylmethyl-5-[2-(2,6-dichlorophenyl)-5- 474
    phenyl-3H-imidazol-4-yl]-2-methyl-3H-imidazo[4,5-
    b]pyridine methanesulfonate
    44 5-(2-Cyclopropyl-5-phenyl-3H-imidazol-4-yl)-3- 386
    (2,2-dimethylpropyl)-2-methyl-3H-imidazo[4,5-
    b]pyridine methanesulfonate
    45 5-[2-(2,6-Dichlorophenyl)-5-phenyl-3H-imidazol- 490
    4-yl]-3-(2,2-dimethylpropyl)-2-methyl-3H-
    imidazo[4,5-b]pyridine methanesulfonate
    • EXAMPLE 46
  • 5-[2-(2-Chloro-6-fluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridine methanesulfonate
  • Reduce {6-[2-(2-chloro-6-fluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitropyridin-2-yl}-(2,2-dimethylpropyl)amine essentially as described in EXAMPLE 15. React the diamine with refluxing neat triethylorthoformate for 24 h and at RT for an additional 24 h. Purify and isolate the free base essentially as described in EXAMPLE 36 (0.11 g, 49% yield). Convert to the methanesulfonate essentially as described in EXAMPLE 1.
  • MS (ES): m/z=460 [M+H].
  • The compounds of EXAMPLE 47-48 may be prepared essentially as described in EXAMPLE 46.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H]
    47 5-(2-Cyclopropyl-5-phenyl-3H-imidazol-4-yl)-3- 372
    (2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridine
    methanesulfonate
    48 5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4- 430
    yl]-3-isobutyl-3H-imidazo[4,5-b]pyridine
    methanesulfonate
    • EXAMPLE 49
  • 5-[3 -(4-Fluorophenyl)-1-isopropylpyrazol-4-yl]-3H-3-isobutylimidazo[4,5-b]pyridin-2-ylamine di-methanesulfonate
  • Add sodium hydrosulfite (2.55 g, 14.6 mmol) to a solution of 2-isobutylamino-3-nitro-6-[3-(4-fluorophenyl)-1-isopropylpyrazol-4-yl]pyridine (0.50 g, 1.27 mmol) in 25 mL of 1:1 THF:H2O, in the presence of NH4OH (8.70 mL, 32% in H2O). Dilute with water (25 mL) after 2 h. Extract with EtOAc (100 mL), dry with MgSO4, and concentrate. Dissolve the residue in 1:1 CH2Cl2:EtOH (25 mL), add cyanogen bromide (0.16 g, 1.51 mmol), and stir for about 48 h. Concentrate and purify the residue (silica gel chromatography, eluting with EtOAc:MeOH 16:1). Recrystallize from diethyl ether:hexanes to provide the free base (0.44 g, 88%). Convert to the methanesulfonate essentially as described in EXAMPLE 1 (58% yield).
  • MS (ES): m/z=393 [M+H].
  • The compounds of EXAMPLE 50-62 may be prepared essentially as described in EXAMPLE 49.
  • MS
    (ES):
    m/z
    EXAM- [M +
    PLE Compound H]
    50 5-[2-tert-Butyl-5-phenyl-1H-imidazol-4-yl]-3-isobutyl- 389
    3H-imidazo[4,5-b]pyridin-2-ylamine di-
    methanesulfonate
    51 5-[2-(2-Fluoro-6-chlorophenyl)-5-phenyl-1H-imidazol- 461
    4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    52 5-[2-Cyclopropyl-5-phenyl-1H-imidazol-4-yl]-3- 373
    isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    53 5-[2-(2-Fluoro-6-trifluoromethylphenyl)-5-phenyl-1H- 495
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    54 5-[2-(2-Fluoro-6-chlorophenyl)-5-(4-fluorophenyl-1H- 479
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    55 5-[2-isopropyl-5-phenyl-1H-imidazol-4-yl]-3-isobutyl- 375
    3H-imidazo[4,5-b]pyridin-2-ylamine di-
    methanesulfonate
    56 5-[2-(2-Fluoro-6-trifluoromethylphenyl)-5-(2,4- 531
    difluorophenyl-1H-imidazol-4-yl]-3-isobutyl-3H-
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    57 5-[2-tert-Butyl)-5-(2,4-difluorophenyl-1H-imidazol-4- 425
    yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    58 5-[2-Isopropyl)-5-(2,4-difluorophenyl-1H-imidazol-4- 411
    yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    59 5-[2-(2-Fluoro-6-chlorophenyl)-5-(2,4-difluorophenyl- 497
    1H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    60 5-[2-Cyclopropyl-5-(2,4-difluorophenyl)-1H-imidazol- 409
    4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    61 5-[2-Cyclopropyl-5-(4-fluorophenyl)-1H-imidazol-4- 391
    yl]-3-isobuty]-3H-imidazo[4,5-b]pyridin-2-ylamine di-
    methanesulfonate
    62 5-[2-tert-Butyl-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3- 407
    isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine di-
    methanesulfonate
    • EXAMPLE 63
  • N′-{5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3 -isobutyl-311-imidazo[4,5-b]pyridin-2-yl}-N,N-dimethylformamidine
  • Reflux N′-5-[2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine prepared essentially as described in EXAMPLE 1 (0.10 g, 0.225 mmol), N, N-dimethylfom-lamide dimethyl acetal (0.05 mL, 0.4 mmol) in toluene (1.5 mL) for 2 h. Cool to RT and concentrate. Purify (silica gel chromatography, eluting with 1:1 CH2Cl2 acetonitrile) to give the title compound (0.11 g).
  • MS (ES): m/z=500 [M+H].
  • The compound of EXAMPLE 64 may be prepared essentially as described in EXAMPLE 63.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H]
    64 N′-{5-[2-(2,6-Dichlorophenyl)-5-phenyl-3H- 533
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-
    2-yl}-N,N-dimethylformamidine
    • EXAMPLE 65
  • N′-{5-[2-(2,6-Dichlorophenyl)-3-methyl-5-phenyl-3H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-yl }-N,N-methylformamidine
  • Stir N′-(5-[2-(2,6-dichlorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-yl)-N,N-dimethylformamidine prepared essentially as described in EXAMPLE 63 (0.10 g, 0.188 mmol), iodomethane (0.040 g, 0.282 mmol), and Cs2CO3 (0.09 g, 0.28 mmol) in DMF (1.5 mL) at RT for about 24 h. Extract with EtOAc and wash with water (3×), saturated aqueous NaCl, then dry over Na2SO4. Filter and concentrate to give a mixture of methyl isomers. Purify (silica gel chromatography) eluting with 1:1:0.4 CH2Cl2:acetonitrile:hexanes to give the title compound (0.02 g).
  • MS (ES): m/z=548 [M+H].
    • EXAMPLE 66
  • 5-[2-(2,6-Difluorophenyl)-3-methyl-5-phenyl-3H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamide
  • Heat N′-{5-[2-(2,6-difluorophenyl)-3-methyl-5-phenyl-3H-imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-yl}-N,N-dimethylformamidine (0.02 g, 0.04 mmol) in 1:1 glacial acetic acid:concentrated HCl (0.6 mL) at 100° C. for 30 min. Cool to RT. Add CH2Cl2 and water, neutralize with SN NaOH to about pH=7 with rapid stirring. Extract the aqueous phase 3× with CH2Cl2, combine organic layers, wash with saturated aqueous NaCi and dry over Na2SO4. Filter and concentrate to give the title compound (0.02 g).
  • MS (ES): m/z=459 [M+H]
  • The compound of EXAMPLE 67 may be prepared essentially as described in EXAMPLE 66.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H])
    67 5-[2-(2,6-Dichlorophenyl)-3-methyl-5-phenyl-3H- 493
    imidazol-4-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-
    2-ylamine
    • EXAMPLE 68
  • 3 -(2,2-Dimethylpropyl)-5-(5-phenyl-3H-[1,2,3]triazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-ylamine methaniesulfonate
  • Suspend (2,2-dimethyl-propyl)-[3-nitro-6-(5-phenyl-3H-[1,2,3]triazol-4-yl)pyridin-2-yl]amine (0.180 g, 0.51 mmol), and 10% Pd/C (0.025 g) in EtOH (10 mL) and stir at RT under a balloon containing hydrogen for 5 h. Filter the reaction mixture using a filtering agent and concentrate to approximately half the reaction volume. Use the diamine immediately without further isolation or purification (MS (ES): m/z 323 [M+H], and treat with cyanogen bromide (0.09 g) in EtOH (5 mL). Stir under nitrogen for 3.5 h, quench with saturated aqueous NaHCO3 (2.0 mL), stir, dilute with CH2Cl2 (5 mL) and H2O (5 mL), and separate the phases. Extract the aqueous phase with CH2Cl2 (2×5 mL), wash the combined organic phases with 5 mL each of H2O and saturated aqueous NaCl, and dry with MgSO4. Filter and concentrate. Purify the residue (silica gel chromataography, eluting with 4:96 2.0 N ammonia in MeOH:CH2Cl2) to give the free base. Convert to the methanesulfonate salt by treatment of a MeOH-water solution with methanesulfonic acid followed by lyophilization to give the title compound (0.07 g, 39%).
  • MS (ES): m/z=348 [M+H].
  • The compounds of EXAMPLE 69-71 may be prepared essentially as described in EXAMPLE 68.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H])
    69 3-(2,2-Dimethylpropyl)-5-[5-(4-fluorophenyl)-3H- 364
    [1,2,3]triazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    70 3-Cyclopropylmethyl-5-[5-(4-fluorophenyl)-3H- 350
    [1,2,3]triazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    71 3-Cyclopropylmethyl-5-(5-phenyl-3H-[1,2,3]triazol- 332
    4-yl)-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    • EXAMPLE 72
  • 5-[2-(2-Chloro-6-fluorophenyl)-5-phenyl-1H-imidazol-4-yl]-3-isobutyl-3H-[1,2,3]triazolo[4,5-b]pyridine methanesulfonate
  • Add dropwise a solution of 6-[2-(2-chloro-6-fluorophenyl)-5-phenyl-1H-imidazol-4-yl]-N2-isobutylpyridine-2,3-diamine (1.1 g, 2.52 mmol) in CH2Cl2 (9 mL) and 50% aqueous AcOH (9 mL) to a solution of sodium nitrite in water (0.1 mL) (0.184 g, 2.66 mmol). Stir the reaction mixture for 15 min, add additional CH2Cl2 and wash the organic layer with a saturated aqueous solution of NaCl, aqueous NaHCO3 (5%), dry with MgSO4, and concentrate. Purify the residue (silica gel chromatography, eluting with 4:1 to 1:2 hexane:EtOAc) to give the free base (70%). MS (ES): m/z=447 [M+H]. Add 0.34 mL of a 1 M solution of methanesulfonic acid in CH2Cl2:MeOH 9:1 to a solution of the free base (0.15 g, 0.336 mmol) in 10 mL CH2Cl2:MeOH 9:1. Stir the solution 5 min, concentrate, and triturate the white solid in diethyl ether. Filter the solid to provide the title compound (71%).
  • MS (ES): m/z=447 [M+H].
  • The compounds of EXAMPLE 73-75 may be prepared essentially as described in EXAMPLE 72.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H])
    73 5-[2-(2,6-Dichlorophenyl)-5-phenyl-1H-imidazol- 463
    4-yl]-3-isobutyl-3H-[1,2,3]triazolo[4,5-b]pyridine
    methanesulfonate
    74 5-[2-(2,6-Dichlorophenyl)-5-(2,4-difluorophenyl)- 499
    1H-imidazol-4-yl]-3-isobutyl-3H-[1,2,3]triazolo[4,5-
    b]pyridine methanesulfonate
    75 5-[2-tert-Butyl-5-(4-fluorophenyl)-1H-imidazol-4- 393
    yl]-3-isobutyl-3H-[1,2,3]triazolo[4,5-b]pyridine
    methanesulfonate
    • EXAMPLE 76
  • 2-Amino-5-(2-tert-butyl-5-phenyl-3H-imidazol-4-yl)imidazo [4,5-b]pyridine-3-sulfonic acid dimethylamide methanesulfonate
  • Heat a mixture of 2-amino-5-(2-oxo-2-phenylacetyl)imidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide (0.07 g, 0.20 mmol), trimethylacetaldeliyde (65 μl, 0.6 mmol) and ammonium acetate (0.23 g, 3 mmol) in AcOH (5 mL) at 90° C. for 4 h. Cool to RT. Dilute with a saturated aqueous NaHCO3, and extract with EtOAc. Concentrate the organic phase and purify (silica gel chromatography, eluting with 15:1 CH2Cl2:MeOH) to give the free base (35%). MS (ES): m/z=438 [M+H]. Add 5.4 μl of a solution 1 M methanesulfonic acid in CH2Cl2:MeOH 95:5 to a solution of the free base (0.02 g, 0.054 mmol) in 5 mL CH2Cl2:McOH 95:5. Stir the solution 5 min, concentrate, and triturate the white solid in diethyl ether. Filter the solid to give the title compound (71%).
  • MS (ES): m/z=440 [M+H].
  • The compounds of EXAMPLE 77-79 may be prepared essentially as described in EXAMPLE 76.
  • MS
    (ES):
    m/z
    [M +
    EXAMPLE Compound H])
    77 2-Amino-5-[(2-fluoro-6-chlorophenyl)-5-phenyl-3H- 512
    imidazol-4-yl)]imidazo[4,5-b]pyridine-3-sulfonic
    acid dimethylamide methanesulfonate
    78 2-Amino-5-[(2,6-dichlorophenyl)-5-phenyl-3H- 528
    imidazol-4-yl)]imidazo[4,5-b]pyridine-3-sulfonic
    acid dimethylamide methanesulfonate
    79 2-Amino-5-(2-tert-butyl-5-(2,4-difluorophenyl)-3H- 476
    imidazol-4-yl)imidazo[4,5-b]pyridine-3-sulfonic
    acid dimethylamide methanesulfonate
    • EXAMPLE 80 5-[2-(2,6-Difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-3-(propane-2-sulfonyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Stir a mixture of propane-2-sulfonic acid {3-amino-6-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol-4-yl]-pyridin-2-yl}amide (0.37 g, 0.79 mmol), cyanogen bromide (0.104 g, 0.99 mmol) and lithium methoxide (0.033 g, 0.87 mmol) in methylene chloride (10 mL) for 12 h at RT. Add saturated NaHCO3 (10 mL) and stir for 1 h. Separate the layers and extract with saturated aqueous NaCl. Dry the organic layer over NaSO4, concentrate and purify (silica gel chromatography, eluting with a gradient of 40:60 EtOAC:hexanes to 80:20 EtOAc:hexanes) to give the free base (0.21 g, 54%). MS (ES): m/z=495 [M+H]. Add methanesulfonic acid to a solution of the free base in 1 mL of a 5:1 mixture of methanol:methylene chloride. Concentrate the solution and add diethyl ether. Filter the solid, and dry to give the title compound.
  • MS (ES): m/z=495 [M+H].
  • The compounds of EXAMPLE 81-91 may be prepared essentially as described in EXAMPLE 80.
  • MS
    (ES):
    m/z
    EXA- (M +
    MPLE Compound H)
    81 3-Butyl-5-[2-(2,6-difluorophenyl)-5-phenyl-3H-imidazol- 445
    4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    82 3-Butyl-5-[2-(2-fluorophenyl)-5-phenyl-3H-imidazol-4- 427
    yl]-3H-imidazo[4,5-b]pyridin-2-ylamine, di-
    methanesulfonate
    83 3-Butyl-5-[2-(2-chloro-6-fluorophenyl)-5-phenyl-3H- 461
    imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    84 3-Butyl-5-(2-tert-butyl-5-phenyl-3H-imidazol-4-yl)-3H- 389
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    85 3-Butyl-5-[2-(2-fluoro-6-trifluoromethylphenyl)-5- 495
    phenyl-3H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-
    2-ylamine methanesulfonate
    86 2-Amino-5-(5-(phenyl-2H-[1,2,3]triazol-4- 385
    yl)imidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide
    87 5-[2-(2-Fluoro-6-trifluoromethylphenyl)-5-phenyl-3H- 545
    imidazol-4-yl]-3-(propane-2-sulfonyl)-3H-imidazo[4,5-
    b]pyridin-2-ylamine methanesulfonate
    88 5-(2-tert-Butyl-5-phenyl-3H-imidazol-4-yl)-3-(propane-2- 439
    sulfonyl)-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    89 5-[2-(2,6-Dichlorophenyl)-5-phenyl-3H-imidazol-4-yl]-3- 529
    (propane-2-sulfonyl)-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    90 5-[2-(2-Chloro-6-fluorophenyl)-5-phenyl-3H-imidazol-4- 511
    yl]-3-(propane-2-sulfonyl)-3H-imidazo[4,5-b]pyridin-2-
    ylamine methanesulfonate
    91 3-Butyl-5-[2-tert-butyl-5-(2,4-difluorophenyl)-3H- 425
    imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    • EXAMPLE 92 5-[2-tert-Butyl-4-(4-fluorophenyl)oxazol-5-yl]-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
  • Bubble with nitrogen a suspension of 2-tert-butyl-4-(4-fluorophenyl)oxazole (0.145 g, 0.66 mmol), 5-bromo-3-isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine (0.355 g, 1.32 mmol), cesium carbonate (6.06 g, 18.6 mmol), palladium (II) acetate (0.201 g, 10%) and triphenylphosphine (0.14 g, 0.07 mmol) in DMF (1.5 mL). Heat the reaction at 100° C. overnight, cool to RT and partition between EtOAc and saturated aqueous NaCl. Wash the organic layer with saturated aqueous NaCl. Dry with Na2SO4, filter, concentrate, and purify (silica gel chromatography, eluting with 2% of 2M ammonia/MeOH in CH2Cl2 to give the title compound (0.07 g, 34%).
  • MS (ES): m/z=408 [M+H].
  • The compounds of EXAMPLE 93-96 may be prepared essentially as described in EXAMPLE 92, with the free base converted to the methansutfonate essentially as described in EXAMPLE 1.
  • MS
    (ES):
    m/z
    (M +
    EXAMPLE Compound H)
    93 5-[2-tert-Butyl-4-(2,4-difluorophenyl)oxazol-5-yl]-3- 426
    isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    94 5-[4-(4-Fluorophenyl)-2-isopropyloxazol-5-yl]-3- 394
    isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    95 3-Isobutyl-5-(2-methyl-4-phenylthiazol-5-yl)-3H- 364
    imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
    96 5-[4-(4-Fluorophenyl)-2-methylthiazol-5-yl]-3- 382
    isobutyl-3H-imidazo[4,5-b]pyridin-2-ylamine
    methanesulfonate
    • EXAMPLE 97
  • 2-Amino-5-(2-tert-butyl-5 -(4-fluorophenyl)oxazol-5-yl)imidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide
  • Dissolve 2-amino-5-bromoimidazo[4,5-b]pyridine-3-sulfonic acid dimethylamide (0.05 g, 0.156 mmol) in toluene (3 ml) in a sealed tube. Add 2-tert-butyl-4-(4-fluorophenyl)-5-trimethylstannanyloxazole (0.07 g, 0.17 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.02 g, 0.015 mmol). Heat the mixture at 110° C. for 4 h. Concentrate and purify (silica gel chromatography, eluting with 20:1 CH2Cl2:MeOH) to give the title compound. (14%).
  • MS (ES): m/z=459 [M+H].
  • The compound in EXAMPLE 98 may be prepared essentially as described in EXAMPLE 97, with the free base converted to the methanesulfonate essentially as described in EXAMPLE 1.
  • MS
    (ES):
    m/z
    (M +
    EXAMPLE Compound H)
    98 2-Amino-5-(2-ispropyl-5-(4-fluorophenyl)oxazol-5- 445
    yl)imidazo[4,5-b]pyridine-3-sulfonic acid
    dimethylamide methanesulfonate
    • EXAMPLE 99
  • 5-[2-(2,6-Dichloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Mix 1-[2-amino-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-(4-fluoro-phenyl)-ethane-1,2-dione (19.58 g, 55.24 mmol), 2,6-dichloro-benzaldehyde (15.47 g, 88.39 mmol) and NH4OAc (42.58 g, 552.41 mmol) in glacial acetic acid (200 mL) and stir at 85° C. under nitrogen for 5 h. Concentrate the resulting reaction mixture under reduced pressure. Dissolve the residue in ethyl acetate (2,000 mL) and wash the resulting solution with saturated aqueous sodium bicarbonate (2×1,000 mL each), water (1,000 mL), and saturated aqueous sodium chloride (1,000 mL). Dry the organics over MgSO4, filter, and then concentrate under reduced pressure. Purify by column chromatography, eluting with ethyl acetate-hexanes (1:1), then ethyl acetate hexanes (2:1), then neat ethyl acetate, then 5% of 2N NH3/MeOH in ethyl acetate to give 11.70 g (41.5% yield) of 5-[2-(2,6-dichloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine as an off-white solid. MS(ES+): m/z=509 (M+1).
  • Mix 5-[2-(2,6-dichloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (11.20 g, 21.99 mmol) in methanol (150 mL), and then add a solution of methanesulfonic acid (2.11 g, 21.96 mmol) in methanol (10 mL) dropwise. Stir at room temperature for 20 minutes and then concentrate under reduced pressure. Add ethyl acetate (150 mL), filter resulting slurry, and wash filter cake with diethyl ether (200 mL). Dry the resulting solid in a drying oven at 80° C. under house vacuum for 2 h to give 12.765 g (95% yield) of the title compound as a light-purple solid.
    • 1H-NMR (400 MHz; CD3OD): δ 7.78-7.50 (m, 7H), 7.24-7.20 (m, 2H), 3.86 (s, 2H), 2.70 (s, 3H), 0.85 (s, 9H) TOF-MS [ES+, M+H] Obs. m/z 509.1412, Calc. m/z 509.1423. EXAMPLE 100
  • 3-(2,2-Dimetlhyl-propyl)-5-[5-(4-fluoro-phenyl)-2-(2-fluoro-6-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Mix 1-[2-amino-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-(4-fluoro-phenyl)-ethane-1,2-dione (18.32 g, 51.69 mmol) and 2-fluoro-6-trifluoromethyl-benzaldehyde (15.00 g, 78.08 mmol) and NH4OAc (39.84 g, 516.90 mmol) in glacial acetic acid (200 mL) and stir at 85° C. under nitrogen for 4 h. Concentrate the resulting reaction mixture under reduced pressure. Dissolve the residue in ethyl acetate (2,000 mL) and wash the resulting solution with saturated aqueous NaHCO3 (2×1,000 mL each), water (1,000 mL), and saturated aqueous sodium chloride (1,000 mL). Dry the organics over MgSO4, filter, and then concentrate under reduced pressure. Purify by column chromatography, eluting with neat ethyl acetate, then 2% of 2N ammonia/MeOH in ethyl acetate, then 5% of 2N ammonia/MeOH in ethyl acetate to give 7.38 g 3-(2,2-dimethyl-propyl)-5-[5-(4-fluoro-phenyl)-2-(2-fluoro-6-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine as an off-white solid. Purify the impure fractions by column chromatography, eluting with neat ethyl acetate, then 1% of 2N ammonia/MeOH in ethyl acetate, then 2% of 2N ammonia/MeOH in ethyl acetate, then 3% of 2N ammonia/MeOH in ethyl acetate) to give an additional 4.68 g of the desired compound.
  • MS(ES+): m/z=527 (M+1)
  • Mix 3-(2,2-dimethyl-propyl)-5-[5-(4-fluoro-phenyl)-2-(2-fluoro-6-trifluoromethyl-phenyl)-1H-imidazol-4-yl]-3H-imidazo[4,5-b]pyridin-2-ylamine (11.56 g, 21.95 mmol) in methanol (150 mL), and then add a solution of methanesulfonic acid (2.11 g, 21.96 mmol) in MeOH (10 mL) dropwise. Allow the resulting reaction mixture to stir at room temperature for 20 minutes, then concentrate under reduced pressure. Slurry the residue in diethyl ether, filter, and wash with fresh diethyl ether. Dry the resulting solid in a drying oven at room temperature under house vacuum for 48 h to give 12.015 g (87.9% yield) of the title compound as a light-purple solid.
    • 1H-NMR(400 MHz; CD3OD): δ 7.84-7.60 (m, 7H), 7.24-7.20 (m, 2H), 3.86 (s, 2H), 2.70 (s, 3H), 0.85 (s, 9H) TOF-MS [ES+M+H] Obs. m/z 527.1979, Calc. m/z 527.1982. EXAMPLE 101
  • 5-[2-tert-Butyl-5-(2,4-difluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-yl amine methane sulfonate
  • Mix 1-2-amino-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b1pyridin-5-yl]-2-(2,4-difluoro-phenyl)-ethane-1,2-dione (17.36 g, 46.62 mmol) and trimethylacetaldehyde (6.42 g, 74.53 mmol) and NH4OAc (35.93 g, 466.20 mmol) in glacial acetic acid (200 mL) and stir at 85° C. under nitrogen for 4.5 h. Cool to room temperature overnight. Heat the reaction at 85° C. for 5 h, then 100° C. for 3 h, then cool to room temperature overnight.
  • Concentrate the resulting reaction mixture under reduced pressure. Dissolve the residue in EtOAc (2 L) and wash the resulting solution with saturated NaHCO3 (2×1 L), H2O (1 L), and saturated aqueous sodium chloride (1 L). Dry the organics over Na2SO4, filter, and then concentrate under reduced pressure. Purify by column chromatography, eluting with neat EtOAc, then 1% of 2N ammonia/MeOH in EtOAc, then 2% of 2N ammonia/MeOH in EtOAc, then 3% of 2N ammonia/MeOH in EtOAc) to give 10.28 g of 5-[2-tert-butyl-5-(2,4-difluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine as an off-white solid.
  • MS(ES+): m/z=439 (M+1)
  • Mix 5-[2-tert-butyl-5-(2,4-difluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (11.55 g, 26.33 mmol) in MeOH (150 mL), and then add a solution of methanesulfonic acid (2.53 g, 26.33 mmol) in MeOH (10 mL) dropwise. Stir the resulting reaction mixture at room temperature for 20 minutes, then concentrate under reduced pressure. Slurry the residue in Et2O, then filter and wash with fresh Et2O. Dry the resulting solid in a drying oven at room temperature under house vacuum overnight, then at 80° C. for 1.5 h. Dissolve the salt in MeOH and then treat with NaHCO3 until basic. Extract the resulting solution with EtOAc, dry the combined organics over Na2SO4, filter, then concentrate under reduced pressure. Purify by column chromatography, eluting with neat EtOAc, then 1% of 2N ammonia/MeOH in EtOAc, then 2% of 2N ammonia/MeOH in EtOAc to give 9.38 g of 5-[2-tert-butyl-5-(2,4-difluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine. Mix 5-[2-tert-butyl-5-(2,4-difluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (9.38 g, 21.39 mmol) in anhydrous MeOH (150 mL), and then add a solution of methanesulfonic acid (2.06 g, 21.43 mmol) in MeOH (10 mL) dropwise. Allow the resulting reaction mixture to stir at room temperature for 30 minutes, then concentrate under reduced pressure. Slurry the residue in Et2O, then filter and wash with fresh Et2O. Dry the resulting solid in a drying oven at room temperature under house vacuum for 48 h to give 10.695 g (76% yield) of the title compound as a tan solid.
    • 1H-NMR (400 MHz; CD3OD): δ 7.74-7.66 (m, 2H), 7.60-7.54 (m, 1H), 7.15-7.08 (m, 2H), 3.70 (s, 2H), 2.70 (s, 3H), 1.51 (s, 9H), 0.81 (s, 9H)
  • TOF-MS [ES+, M+H]: Obs.: m/z=439.2398; Calc.: m/z=439.2422
    • EXAMPLE 102
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Stir a suspension of {6-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(2,2-dimethylpropyl)-amine (426 mg, 1.0 mmol) and 10% palladium on carbon (85 mg) in 100% ethanol under hydrogen from a balloon overnight. Filter the suspension through a 0.2 μm syringe filter and concentrate under reduced pressure. Dissolve the residue in 10% aqueous ethanol and treat at room temperature with cyanogen bromide (80 mg, 0.75 mmol, 1.5 equiv). When the reaction is complete, quench the reaction with saturated aqueous NaHCO3. Add ethyl acetate and water to dissolve all solids. Wash the organic layer once with saturated aqueous NaHCO3, once with saturated aqueous NaCl, dry with Na2SO4, filter, and concentrate under reduced pressure. Subject the residue to medium pressure silica gel chromatography eluting with 50% ethyl acetate/CH2Cl2 then with a gradient of 1.5-3.5% (2M ammonia in MeOH)/CH2Cl2) to provide 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine as a brown foam (156 mg, 74% yield).
  • Treat a solution of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in methanol-water with methanesulfonic acid followed by lyophilization to provide the title compound. Exact MS calc.: m/z=421.2516 (M+H)+; found: m/z=421.2523 (M+H)+.
    • 1H-NMR (DMSO-d6): δ 7.85 (d, 1H, J=7.9 Hz), 7.85 (d, 1H, J=7.9 Hz), 7.72 (d, 1H, J=8.4 Hz), 7.62 (dd, 2H, J=8.8, 4.8 Hz), 7.27 (t, 2H. J=8.8 Hz), 3.90 (s, 2H), 2.70 (s, 3H), 1.62 (s, 9H), 0.89 (s, 9H) EXAMPLE 103
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine fumarate
  • Dissolve 126 mg (0.3 mmol) 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in 1.0 ml 88% acetone*. Add a solution of 70 mg fumaric acid in warm 88% acetone* incrementally with shaking.
  • Add seed crystals and filter the resultant precipitate. Air dry to provide 145 mg (74%) of slight purple hair-like crystals. *(remainder water by volume)
    • EXAMPLE 104
  • Crystalline 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfoniate
  • Dissolve 126 mg (0.3 mmol) 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in 2.0 ml acetone. Add 58 mg methanesulfonic acid incrementally. Add seed crystals and filter the resultant precipitate. Air dry to provide 114 mg (62%) of off-white irregular crystals. m.p. >250° C.
    • EXAMPLE 105
  • Amorphous 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo [4,5-b]pyridin-2-ylamine dimethanesulfonate
  • Dissolve 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3 -(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate (300 mg) in 5 mL deionized water. Filter solution through a 0.45 μm filter into a pre-chilled 500 mL volumetric flask. Rapidly freeze solution on bottom and sides of flask. Freeze dry for 24 hours to provide amorphous 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate.
    • EXAMPLE 106
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine succinate
  • Dissolve 126 mg (0.3 mmol) 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in 2.0 mL 88% acetone*. Add a solution of 71 mg succinic acid in 1 mL warm 88% acetone* incrementally. Add seed crystals and filter the resultant precipitate. Air dry to provide 123 mg (63%) of very light purple crystals.
  • *(remainder water by volume)
    • EXAMPLE 107
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3 -(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimaleate
  • Dissolve 126 mg (0.3 mmol) 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in 1.0 mL isopropanol.
  • Add a solution of 69.6 mg maleic acid in 1 mL warm isopropanol incrementally. Add seed crystals and filter the resultant precipitate. Air dry to provide 120 mg (63%) of very light purple crystals.
    • EXAMPLE 108
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dihydrochioride
  • Dissolve 126 mg (0.3 mmol) 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in 2.0 mL acetone. Add 120 μL of 5N hydrochloric acid incrementally. Filter the resultant precipitate. Air dry to provide 140 mg (93%) of very light pink crystals.
    • EXAMPLE 109
  • 5-[2-(2-Chloro-6-fluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Dissolve {6-[2-(2-chloro-6-fluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(2,2-dimethylpropyl)-amine (240mg, 0.50 mmol) in 100% ethanol (10 mL) and add tin(II) dichloride dihydrate (564mg, 2.50 mmol, 5.0 equiv). Heat the reaction mixture until starting material is consumed. Cool the reaction solution to room temperature, quench slowly with saturated aqueous NaHCO3. Add Celite® to the quenched reaction and filter the suspension on a CeliteOR pad with water and ethyl acetate washes. Separate the layers and wash the organic layer with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter, and concentrate under reduced pressure. Add 10% aqueous ethanol and cyanogen bromide (106 mg, 1.00 mmol, 2.0 equiv) to the resulting solid and stir overnight. Quench the reaction with saturated aqueous NaHCO3 (20 mL).
  • Add ethyl acetate and water to dissolve all solids. Wash the organic layer three times with saturated aqueous NaCl, dry with Na2SO4, filter, and concentrate under reduced pressure. Subject the residue to medium pressure silica gel chromatography eluting with a gradient of 1.5-3% (2M ammonia in MeOH)/CH2Cl2 to provide 5-[2-(2-Chloro-6-fluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo [4,5-b]pyridin-2-ylamine as a yellow-green solid (196 mg, 60% yield).
  • Treat a solution of 5-[2-(2-Chloro-6-fluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in methanol-water with methanesulfonic acid followed by lyophilization to provide the title compound.
  • MS(ESI): m/z=475.2 (M+H)+.
    • EXAMPLE 110
  • 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-(1(R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Dissolve {6-[2-tert-butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(1(R),2,2-trimethyl-propyl)-amine (558 mg, 1.27 mmol) in 100% ethanol (15 mL) and add tin(II) dichloride dihydrate (1.4 g, 6.3 mmol, 5 equiv). Heat the reaction mixture until starting material is consumed. Cool the reaction solution to room temperature, quench slowly with saturated aqueous NaHCO3. Add CeliteOR and filter the suspension on a Celite® pad, washing with water and ethyl acetate. Separate the layers and wash the organic layer with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter, and concentrate under reduced pressure. Add 10% aqueous ethanol (13 mL) and cyanogen bromide (202 mg, 1.99 mmol, 1.5 equiv) to the residue and stir overnight. Add another 1.5 equiv of cyanogen bromide, stir 3 h, and quench with saturated aqueous NaHCO3 (20 mL). Add ethyl acetate and water to dissolve all solids. Wash the organic layer three times with saturated aqueous NaCl, dry with Na2SO4, filter, and concentrate under reduced pressure. Subject the residue to medium pressure silica gel chromatography eluting with a gradient of 1.5-4% (2M ammonia in MeOH)/CH2Cl2 to provide 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-( 1(R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine as a tan glass (158 mg, 29% yield).
  • Treat a solution of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-(1(R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in methanol-water with methanesulfonic acid followed by lyophilization to provide the title compound.
  • MS(ESI): m/z=435.2 (M+H)+
    • EXAMPLE 111
  • 5-[2-(2,6-Difluoro-phenyl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-(1 (R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine methanesulfonate
  • Dissolve {6-[2-(2,6-difluoro-phenyl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-nitro-pyridin-2-yl}-(1(R),2,2-trimethyl-propyl)-amine (673 mg, 1.4 mmol) in 100% ethanol (15 mL) and add tin(II) dichloride dihydrate (1.5 g, 6.8 mmol, 5 equiv). Heat the reaction mixture until starting material is consumed. Cool the reaction solution to room temperature, quench slowly with saturated aqueous NaHCO3. Add Celite® to the quenched reaction and filter the suspension on a Celite® pad, washing with water and ethyl acetate. Separate the layers and wash the organic layer with saturated aqueous NaCl. Dry the organic layer with Na2SO4, filter, and concentrated under reduced pressure. Add 10% aqueous ethanol (14 mL) and cyanogen bromide (216 mg, 2.04 mmol, 1.5 equiv) to the residue and stir overnight. Quench with saturated aqueous NaHCO3 (20 mL). Add ethyl acetate and water to dissolve all solids. Wash the organic layer is with saturated aqueous NaCl, dry with Na2SO4, filter, and concentrate under reduced pressure.
  • Subject the residue to medium pressure silica gel chromatography eluting with a gradient of 1.5-3% (2M ammonia in MeOH)/CH2Cl2 to provide 5-[2-(2,6-difluoro-phenyl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-(1 (R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine as a tan glass (289 mg, 43% yield).
  • Treat a solution of 5-[2-(2,6-difluoro-phenyl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3-(1(R),2,2-trimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine in methanol-water with methanesulfonic acid followed by lyophilization to provide the title compound.
  • MS(ESI): m/z=491.2 (M+H)−
    • EXAMPLE 112
  • 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate
    5-Bromo-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-yl-ammonium bromide
  • Stir a mixture of hypophosphorous acid 50 wt. % aq. sol'n (0.555 g) and 5% Pt/C (2.5 g) in H2O (20 mL, 0.4 vol.) for 10 minutes. Add solid VO(acac)2 (0.420 g, 1.20 mmol) and stir the dark slurry for an additional 5 minutes. Charge this slurry to a mixture of 2-(2,2-dimethylpropylamino)-3-nitro-6-bromopyridine (50.00 g, 173.61 mmol) in toluene (500.00 mL) in a one liter autoclave at ambient temperature. Heat the autoclave to 75° C. in the presence of 112 at 35 psi (2.38 atmospheres) with stirring at 100 rpm. After 3 hours filter the reaction mixture over a Hyflo Super Celo pad and concentrate the filtrate under reduced pressure to one half of the overall mass (273.0 g) of the solution. Stir the solution and add cyanogen bromide (18.4 g, 173.70 mmol) followed by MeOH (250 mL). After 18 h, heat to 40° C. and concentrate under reduced pressure until 350 mL of solvent is collected via short path distillation. Dilute the resulting slurry with MTBE (350 mL, 7.0 vol.), cool to 0° C., and stir 1 h. Filter off solid, wash with MTBE (75 mL, 1.5 vol.), and dry under reduced pressure at 40° C. for 24 h to provide 48.06 g (76%) of the desired compound as a white solid.
    • 1H-NMR (300 MHz, DMSO-d6): δ 0.96 (9H, s), 3.91 (2H, s), 7.45 (1H, d, J=8.1 Hz), 7.64 (1H, d, J=8.1 Hz), 8.73 (2H, bs).
  • MS(ES−): m/z=282.0; (M−1)−
    3-(2,2-Dimethyl-propyl)-5-(4-fluoro-phenylethynyl)-3H-imidazo[4,5-b]pyridin-2-ylamine
  • Add triethylamine (27.10 g, 267.80 mmol) to a mixture of 5-bromo-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-yl-ammonium bromide (25.00 g, 68.67 mmol) in ethanol (25 mL) and toluene (75 mL). Heat to 70-75° C. and then add Pd(OAc)2 (0.15 g, 0.69 mmol), triphenylphosphine (0.72 g, 2.75 mmol), and copper (I) iodide (0.13 g, 0.69 mmol). Add ⅔ of a solution of 4-fluorophenylacetylene (12.37 g, 103.00 mmol) in toluene (50 mL, 2.0 vol.) over 15 minutes. Add the remaining 4-fluoroacetylene solution after 1 h. After 3 h, add additional 4-fluorophenylacetylene (1.5 g, 12.86 mmol). After an additional hour, remove EtOH by distillation. Cool the reaction mixture to <40° C. and add water (25 ml). Cool to room temperature. Filter suspension and wash with water (25 mL) and 2×25 mL toluene. Dry under reduced pressure at 45-50° C. to provide 19.3 g (87%) of the desired compound.
    • Purification Step
  • Add methanol (1,200 mL) to combined lots of 3-(2,2-dimethyl-propyl)-5-(4-fluoro-phenylethynyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (37.30 g) and heat to reflux. Add activated charcoal (3.73 g, 10 wt %) and reflux for 1 h. Filter while slurry is hot, then add water (375 mL) to the filtrate with stirring at room temperature. Filter off solids, wash 2×100 mL water and dry under reduced pressure at 45-50° C. to provide 30.0 g (80%) of the desired compound.
    • 1H-NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s), 3.91 (2H, s), 6.98 (2H, s), 7.25-7.32 (3H, m), 7.40 (1H, d, J=7.8 Hz), 7.62-7.67 (2H, m).
  • 1 -[2-Amino-3 -(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-(4-fluoro-phenyl) ethane-1,2-dione
  • Add MgSO4(82.7 g, 687.05 mmol) and NaHCO3 (14.4 g, 171.41 mmol) in deionized water (1524 mL) over 5 minutes to a stirring solution of 3-(2,2-dimethyl-propyl)-5-(4-fluoro-phenylethynyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (110.76 g, 343.57 mmol) in acetone (3665 mL). Add Hyflo Super Cel (171.1 g) followed by KMnO4 (108.6 g, 687.21 mmol). Heat at 40-45° C. for 3 hours and then cool to room temperature. Add saturated aqueous Na2SO3 (1,800 mL) followed by EtOAc (3,500 mL) and water (3,500 mL). Filter through bed of Hyflo Super Celd washing with a mixture of 9% MeOH/EtOAc (2,860 mL). Separate layers of filtrate, back-extract aqueous layer 2×2,750 mL EtOAc. Combine organic extracts, wash 2×2,380 mL saturated aqueous sodium chloride (4760 mL), and dry over Na2SO4. Filter, then concentrate under reduced pressure to provide a dark-red-brown solid (185 g). Add acetone (650 mL), filter suspension, wash collected solid 3×167 mL MTBE (501 mL), and dry under reduced pressure at 45° C. to provide 106.79 g (88%) of the desired compound as a light yellow solid.
  • 1H-NMR (500 MHz, DMSO-d6): δ 0.72 (9H, s), 3.71 (2H, s), 7.47 (2H, dd, J1=7.5 Hz, J2=8.5 Hz), 7.56 (2H, bs), 7.65 (1H, d, 8.0 Hz), 7.97-7.99 (2H, m), 8.02 (1H, d, J=8.0 Hz).
    MS(ES+): m/z=355.4; (M+1)+
    5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine
  • Heat a mixture of 1-[2-amino-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-(4-fluoro-phenyl)-ethane-1,2-dione (25.33 g, 71.48 mmol), NH4OAc (82.3 g, 1.04 mol), and trimethyl-acetaldehyde (13.0 mL, 116 mmol), in MeOH (650 mL) to reflux under nitrogen for 20 h. Concentrate under reduced pressure. Dissolve residue in EtOAc (2,000 mL), deionized water (500 mL), and saturated aqueous NaHCO3 (1000 mL).
  • Separate the layers and wash organic layer with 1 L saturated aqueous NaHCO3 (1000 mL), deionized water (500 mL), and saturated aqueous sodium chloride (500 mL), then dry over Na2SO4. Filter and concentrate under reduced pressure to provide 20.08 g of a dark solid/foam. Add MTBE (60 mL) and heat to reflux. Add hexane (290 mL) over 5 min. then cool slurry to room temperature. Stir 1.25 h, filter, wash collected solid with hexane (80 mL), and dry under reduced pressure at 45° C. overnight to provide 17.31 g (58%) of the desired compound as a light tan solid.
    • Purification Step
  • Heat a mixture of combined lots of 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (55.9 g) in MTBE (165 mL) to reflux. Add hexane (800 mL) and cool slurry to room temperature. Filter solid, wash with hexane (200 mL), and dry under reduced pressure at 45° C. to provide 54.35 g (97%) of the desired compound as a light tan solid.
  • 1H-NMR (300 MHz, CD3OD): δ 0.87 (9H, s), 1.45 (9H, s), 3.79 (2H, s), 7.05 (2H, dd, J1=8.7 Hz, J2=9.0 Hz), 7.30 (1H, bs), 7.40-7.50 (3H, m).
    MS(ES+): m/z=421.4 (M+1)+
    5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate
  • Heat a solution of 5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (10.0853 g, 23.98 mmol) in MeOH (24 mL) to 40° C. Remove heat source and add methanesulfonic acid (3.14 mL, 47.91 mmol) in EtOAc (10 mL) dropwise over 3.5 minutes. Stir for 1 h while cooling to room temperature. Add EtOAc (20 mL) and stir 5 minutes. Filter, wash solid with 2×50 mL EtOAc, and dry under reduced pressure at 45-50° C. for 2.5 h to provide 12.62 g (86%) of the title compound as a white powder solid.
    • 1H-NMR (500 MHz, CD3OD): δ 0.94 (9H, s), 1.65 (9H, s), 2.73 (61, s), 3.91 (2H, s), 7.31-7.35 (2H, m), 7.63-7.67 (2H, m), 7.69 (1H, d, J=8.5 Hz), 7.87 (1H, d, J=8.5 Hz).
  • MS(ES+): m/z=421.5 (M+1)+
    • EXAMPLE 113
  • 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3 -(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate
    2-Amino-3-(2,2-dimethyl-propyl)-5-[2-(4-fluorophenyl)-2-oxo-acetyl]-3H-imidazo[4,5-b]pyridin-1-ium methanesulfonate
  • Heat a mixture of 3-(2,2-dimethyl-propyl)-5-(4-fluoro-phenylethynyl)-3H-imidazo[4,5-b]pyridin-2-ylamine (184.7 g, 0.573 mol), formic acid (923.0 mL), methanesulfonic acid (110.0 g, 1.14 mol), DMSO (224.0 g, 2.87 mol), and 48% HBr (9.7 g, 0.057 mol) at gentle reflux (105-107° C.) with a distillation device overnight. Distill out volatiles (550 mL) under reduced pressure. Cool to about 65° C. and add water (1.2 L) containing Na2S2O3 (18:0 g, 0.114 mmol) dropwise with rigorous stirring, maintaining the temperature at about 65° C. Cool reaction mixture to ambient (about 3 hours), then in ice bath (about 30 minutes). Filter solid, rinse with water (200 mL), and dry in vacuum oven at about 50 ° C. to provide 217.0 g (84%) or the desired compound.
    • 1H NMR(300 MHz, DMSO-d6): δ 9.08 (s, 2H); 8.18 (d, J=6.0 Hz, 2H); 7.92-7.98 (m, 3H); 7.40 (t, J=8.0 Hz, 2H); 3.67 (s, 2H); 2.40 (s, 2H); 0.66 (s, 9H).
  • MS(ES+): m/z=355.4(M+1)+.
    • Ring Formation
  • Heat a mixture of 2-amino-3-(2,2-dimethyl-propyl)-5-[2-(4-fluorophenyl)-2-oxo-acetyl]-3H-imidazo[4,5-b]pyridin-1-ium methanesulfonate (0.62 mol), ethanol (2.5 L), ammonium acetate (500.0 g, 6.2 mol), and trimethyl acetaldehyde (84.0 g, 0.93 mol) at about 70° C. overnight. Evaporate the volatiles. Add ethyl acetate (4.0 L) and water (3.0 L) followed by 1.0 N NaOH (1.2 L) and stir for 20-30 minutes at room temperature.
  • Separate the phases and extract the aqueous phase with ethyl acetate (2.0 L). Combine the ethyl acetate phases, wash twice with 10 volumes of saturated aqueous sodium chloride, treat with Darco (30.0 g, 10% by weight). Filter through a pad of Celite and concentrate the filtrate to about 1.0 L). Add ethanol (2.50 L) and heat to about 65 ° C. and add methanesulfonic acid (150.0 g. 1.55 mol) in ethyl acetate (500 mL) in fast drops, maintaining the temperature at about 65° C. for 3 hours. Cool the reaction mixture to room temperature with stirring for 2 more hours. Filter the suspension, rinse the solid with ethyl acetate (500 mL), and dry in vacuum oven at about 45° C. to provide 226.0 g of the title compound.
  • 1H-NMR(300 MHz, DMSO-d6): δ 8.99 (s, 2H), 7.90 (d, 1H, J=9.0 Hz); 7.86 (d, 1H, J=9.0 Hz); 7.60 (dd, 2H, J=9.0 Hz), 7.34 (dd, 2H, J=9.0 Hz); 3.68 (s, 2H); 2.35 (s, 6H); 1.51 (s, 9H); 0.71 (s, 9H).
    • MS(ES+): m/z =421.5 (M+1)+. EXAMPLE 114 General Procedure for the Preparation of Seed Crystals
  • A master plate is prepared with 250 μL of the free base of the subject compound in methanol (0.1 M) added to all wells set in a 96 well format. An array of acids is dispensed to each well in one and two molar equivalents. The solvents are evaporated from all 96 wells using a Genevac Series II evaporator leaving solid residue in the master plate. An array of solvents is dispensed to each one of these wells through a cap mat and then heated to 55° C. with stifling and allowed to equilibrate for 60-90 minutes at about 55° C. Each sample is then filtered hot and transferred to corresponding wells in an evaporation plate, a precipitation plate, and a cooling plate. The evaporation plate is prepared by transferring 200 μL of the filtrate from the master plate using 55° C. heated syringes to the open well titer plate and is then allowed to evaporate to dryness over night at room temperature and ambient humidity. The precipitation plate is prepared by adding 100 μL of the filtrate from the master plate using 55° C. heated syringes to capped 96 well titer plate where each well contains an anti-solvent of 200 μL of heptane or 2-propanol.
  • After equilibrating for a period of nine hours at room temperature, the excess solution is wicked away using pre-cut Whatman filter paper. The cooling plate is prepared by transferring 200 μL of the filtrate from the master plate to individual wells using 55° C. heated syringes in a capped titer plate, and cooling exponentially from 55 to 10° C. over a period of 8 hours. Photomicrographs are collected on the material at the bottom of each well in the 96 well plates using a Zeiss Axiovert 200M inverted incident-light microscope with a 2.5× objective. If the material is crystalline, it exhibits birefringence that is displayed as white against a dark background. Amorphous solids appear dark or as opaque droplets or rings.
    • Inhibition of p38 Kinase Standard Solution Preparations
  • The kinase buffer solution is prepared by combining 2.5 mL 1 M Tris-HCl (pH 7.5), 0.1 mL 1 M dithiothreitol, 1.0 mL 1 M magnesium chloride, and 300 μL 1% Triton X-100 and diluting to 100 mL with water. 84 mL of this kinase buffer solution is combined with 16 mL DMSO to prepare the 16% DMSO solution.
  • The 200 μM ATP solution is prepared by adding 102.6 μL 10 mM aqueous ATP, 25 μL 33P-ATP, and 163.5 μL of 4 mM aqueous Epidermal Growth Factor Peptide 661-681 (Biomol, Catalog #P-121) in 5 mL kinase buffer solution.
  • p38 kinase enzyme solution is prepared by dissolving 9.5 μL concentrated enzyme solution (250 ng p38 enzyme/μL kinase buffer solution) in 1536 μL kinase buffer solution.
    • Sample Preparation
  • An 80 μM solution of each test compound and control compound are prepared by dissolving 2 μL of a 10 mM stock solution of the respective compounds in dimethylsulfoxide in 248 μL of the 16% DMSO solution in a Costar 96-well microtiter plate. The plate is placed onto the Tecai Genesis automated liquid handler for 1:3 serial dilutions.
    • Assay
  • 10 μL of serially diluted compound is placed with a Beckman Multimek 96-well automated liquid handler to the assay plate. 20 μL of 200 μM ATP solution is added with a Titertek Multidrop 8-channel liquid handler. 10 μL of p38 kinase enzyme solution is transferred to the assay plate using the Multimek. The mixture is allowed to react for 40 min at 30° C. and then the reaction is stopped by adding 60 μL of freshly prepared 5% glacial AcOH with Multidrop. 80 μL of this solution is transferred to an “MAPH” plate using the Multimek. The plates are allowed to set for 30 min at RT and then washed/aspirated on the Titertek MAP extractor with freshly prepared 0.5% glacial AcOH (1×300 μL, 2×200 μL). The wells are blotted and 100 μL MicroScint-20 scintillation fluid (Packard Bioscience) is added with the Multidrop. The plates are allowed to sit for 30 min and counted on a PE/Wallac Microbeta Trilux scintillation counter for 33P-isotope.
  • All exemplified compounds were initially tested at 10 concentrations (20 μM-1 nM using 1:3 serial dilutions). Compounds with IC50 values less than 25 nM were re-tested at a starting concentration of 2 H to 0.1 nM (1:3 serial dilutions). IC50 values were calculated (IDBS ActivityBase software) for each compound using non-linear regression. All exemplified compounds were tested essentially as described above and were found to inhibit the p38 kinase enzyme with an IC50≦5 μM. Specifically, the following compounds were tested essentially as described above and were found to inhibit the p38 kinase enzyme as tabulated below.
  • EXAMPLE IC50 (nM)
    6 7.2
    9 4.6
    11 2.3
    12 3.6
    13 3.3
    18 3.6
    19 3.2

    Inhibition of TNF-α in vitro
    • Mouse Peritoneal Macrophages
  • 1 mL thioglycolate broth (5.0 g yeast extract, 15.0 g casitone or trypticase, 5.0 g dextrose, 2.5 g sodium chloride, 0.75 g L-cystine, 0.5 g sodium thioglycolate, 1.0 mg resazurin, and 0.75 g agar in 1.0 L distilled water) is injected into the peritoneal cavity of Balb/C female mice. At day 4 or 5 post-injection the mice are sacrificed and then injected i.p. with 4 mL RPMI-1640 medium (BioWhittaker) and the peritoneal macrophages are withdrawn by syringe.
    • Cytokine Production
  • Mouse peritoneal microphages are counted with a hemocytometer and adjusted to 5×105 cells/well in 96-well plates in RPMI-1640 medium with 10% fetal bovine serum. 200 μL/well is plated in 96-well plates and the cells allowed to settle and adhere to the bottom of the well for at least 3 h. The test compound or standard p38 kinase inhibitor is pre-treated using a series of 8 concentrations for 1 h at 37° C. (20 μL/well). The cells are treated with a mixture of 50 ng/mL lipopolysaccharide (LPS) and 10 U/mL interferon-γ for 18 h at 37° C. (20 μL/well). The conditioned media is harvested and assayed for TNF-α production using the Luminex procedure.
    • TNF-α/Luminex Detection Assay (Bio-Rad Bio-Plex Kit—Catalog#171-G12221)
  • The lyophilized premixed TNF-α standard (1 standard tube/two 96-well plates) is reconstituted with 50 μL sterile water (500,000 pg/mL). The samples are vortexed for 5 seconds, incubated on ice for 30 min, and vortexed for 5 seconds before use. A set of twelve 1.5 m tubes are labeled with #1-thru #12 and then the amounts of cell media shown below added to the appropriate tubes (standard concentrations are as follows: 50,000; 25,000; 12,500; 6,250; 3,125; 1,562.5; 781.3; 390.6; 195.3; 97.7; 48.8; and 24.4 pg/ml). The premixed anti-cytokine conjugated beads are vortexed (25×) vigorously for 30 seconds. The anti-cytokine conjugated beads are diluted to a 1× concentration using 1× Bio-Plex Assay Buffer. For every plate, 240 μL of the pre-mixed beads is added to 5760 μL of Bio-Plex Assay Buffer. A Millipore 96-well filter plate is blocked with 100 μL/well of blocking buffer. The blocking buffer is filtered through using a Millipore filtration system and then toweled dry. 2 washes are performed on the filter plate with 100 μl/well of Bio-Plex Assay Buffer and toweled dry. The 1× anti-cytokine conjugated beads are vortexed for 15 seconds and added 50 μL to each well.
  • This is filtered through and toweled dry. 2 washes are performed on plates with 100 μl/well of Bio-Plex Wash Buffer. Again, it is filtered through and toweled dry. 50 μL of sample or standard is added to each sample well. This is incubated for 60 seconds at RT on a shaker protected from light at setting 6 and then for 30 min at setting 3 and then placed in the refrigerator overnight. 3 washes are performed with Bio-Plex Wash Buffer. Filter through and toweled dry. The cytokine detection antibody is prepared (˜10 min prior to use) for every plate and 60 μL of the premixed cytokine detection antibody stock is added to 5940 μL of Bio-Plex Detection Antibody Diluent. 50 μL of cytokine detection antibody is added and incubated for 60 seconds at RT on a shaker protected from light at setting 6 and then for 30 min at setting 3.3 washes are performed with the Bio-Plex Wash Buffer. This is filtered through and toweled dry. Strept-PE (˜10 minutes prior to use) is prepared for every plate and 60 μL to 5940 μL of Bio-Plex Assay Buffer added. 50 μL of Streptavidin-PE is added to each well and incubated for 60 seconds at RT on a shaker protected from light at setting 6 and then for 10 min at setting 3.3 washes are performed with Bio-Plex Wash Buffer. This is filtered through. The beads are re-suspended in 100 μL/well of Bio-Plex Assay Buffer. Standards and samples are read on a Luminex machine. These intensity readings are then converted to picogram/milliliter units based on a 12-point standard curve created in duplicate using a four-parameter logistic regression method (Bio-Plex Manager 2.0, Bio-Rad), and the IC50 calculated.
  • Representative members of the exemplified compounds were tested essentially as described above and suppressed TNF-α in vitro with an IC50<100 nM. Specifically, the following compounds were tested essentially as described above and were found to suppress TNF-α in vitro as tabulated below.
  • EXAMPLE IC50 (nM)
    6 <9.1
    9 1.2
    11 2.4
    13 <9.1
    18 <9.1
    19 <9.1
    104 6.3

    Inhibition of TNF-α in vivo
  • Compounds are administered p.o. (100, 30, 10 and 3 mg/kg) to female Balb/c mice (5 mice/dose). After 2 h, lipopolysaccharide (LPS, E. coli serotype 0111:B4, 5 mg/kg) is administered i.v. in the tail vein of each mouse. One hour after LPS administration the mice are asphyxiated by CO2 inhalation and bled out via cardiac puncture.
    • TNF-α/Luminex Detection Assay (Bio-Rad Bio-Plex Kit—Catalog #171-G12221)
  • Reconstitute the lyophilized premixed TNF-α; standard (1 standard tube/two 96-well plates) with 50 μL sterile water (500,000 pg/mL). Gently vortex for 5 seconds, incubate on ice for 30 min, and vortex for 5 seconds before use. Label a set of twelve 1.5 mL tubes with #1-thru #12 and then add the amounts of cell media shown below to the appropriate tubes (standard concentrations are as follows: 50,000; 25,000; 12,500; 6,250; 3,125; 1,562.5; 781.3; 390.6; 195.3; 97.7; 48.8; and 24.4 pg/mL). Vortex the premixed anti-cytokine conjugated beads (25×) vigorously for 30 seconds. Dilute the anti-cytokine conjugated beads to a IX concentration using 1× Bio-Plex Assay Buffer. For every plate, add 240 μL of the pre-mixed beads to 5760 μL of Bio-Plex Assay Buffer. Block a Millipore 96-well filter plate with 100 μL/well of blocking buffer. Filter through the blocking buffer using a Millipore filtration system. Towel dry. Perform 2 washes on the filter plate with 100 μl/well of Bio-Plex Assay Buffer and towel dry. Vortex the 1× anti-cytokine conjugated beads for 15 seconds and add 50 μL to each well. Filter through and towel dry. Perform 2 washes on plates with 100 μl/well of Bio-Plex Wash Buffer. Filter thru and towel dry. Add 25 μL of serum sample and 25 μL of diluent (Bio-Rad) or 50 μL standard to each sample well. Incubate for 60 seconds at RT on a shaker protected from light at setting 6 and then for 30 min at setting 3 and then place in the refrigerator overnight. Perform 3 washes with Bio-Plex Wash Buffer. Filter through and towel dry. Prepare cytokine detection antibody (˜10 min prior to use) for every plate, add 60 μL of the premixed cytokine detection antibody stock to 5940 μL of Bio-Plex Detection Antibody Diluent. Add 50 μL of cytokine detection antibody and incubate for 60 seconds at RT on a shaker protected from light at setting 6 and then for 30 min at setting 3. Perform 3 washes with Bio-Plex Wash Buffer. Filter through and towel dry. Prepare strept-PE (˜10 minutes prior to use) for every plate, add 60 μL to 5940 μL of Bio-Plex Assay Buffer. Add 50 μL of Streptavidin-PE to each well and incubate for 60 seconds at RT on a shaker protected from light at setting 6 and then for 10 min at setting 3. Perform 3 washes with Bio-Plex Wash Buffer. Filter through. Re-suspend the beads in 100 μL/well of Bio-Plex Assay Buffer. Read standards and samples on Luminex machine. These intensity readings are then converted to picogram/milliliter units based on a 12-point standard curve created in duplicate using a four-parameter logistic regression method (Bio-Plex Manager 2.0, Bio-Rad), and the IC50 calculated.
  • Representative members of the exemplified compounds were tested essentially as described above and suppressed TNF-α in vivo with an IC50<100 mg/kg. The compound of EXAMPLE 104 was tested essentially as described above and exhibited an IC50<1 mg/kg.
    • Effect on Intra-Articular LPS Induced TNF-α
  • Intra-articular injection of LPS into rat ankles induces the synthesis of TNF-α, which can be measured in synovial lavage fluid. High levels of TNF-α are detectable within 2 hours. Since the joint is the site where arthritis develops, this model can rapidly determine whether an orally administered compound has an effect on an inflammatory response in the synovium.
  • Six female Lewis rats (150-200 g) are place in each treatment group. The animals are given vehicle (1% NaCarboxymethylcellulose-0.25% Tween 80) or test compound (1 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg) orally. One hour later, 10 μl LPS (10 μg) is administered intra-articularly into the right ankle of each rat, while the left ankle receives 10 μL of saline. After two hours, each ankle is lavaged with 100 μL of saline. The lavage is collected and stored at −80° C.
    • Group#1: Vehicle (1%NaCMC-0.25%Tween 80, 1 mL, PO)
    • Group#2: Test compound (1 mg/kg, 1 mL, PO)
    • Group#3: Test compound (3 mg/kg, 1 mL, PO)
    • Group#4: Test compound (10 mg/kg, 1 mL, PO)
    • Group#5: Test compound (30 mg/kg, 1 mL, PO)
  • TNF-α is measured with a commercially available ELISA kit (R&D, RTA00). Treatment with the compound of EXAMPLE 104 produced a dose-dependent inhibition of TNF-α synthesis with TMED50 of 0.54 mg/kg.
    • B16F10 Melanoma Target (MAPKAP-K2 Phosphorglation)
  • The B 16F10 melanoma cell line is obtained from the American Type Culture Collection, Rockville, Md. The cells are cultured in RPMI-1640 medium supplemented with 10% fetal calf serum. The cells grown in vitro are harvested during their exponential growth phase by gentle trypsinization, washed twice in medium, and resuspended in serum-free RPMI-1640 medium. The number of viable cells is determined using a hemocytometer and adjusted to 1×107/mL. Tumor cells are injected subcutaneously in normal C57B16 mice. hioculum volume per mouse is 0.2 mL (2,000,000 cells). When the tumors reach 300-500 mg, the mice are used for target inhibition studies at either a fixed time (2.5 hours) after p.o. compound treatment or pharmacodynamic studies where the tumors are collected at multiple time-points (e.g., 3, 6, 9, 12, 15, and 18 h) after p.o. compound treatment.
    • Protein Extraction and Immuno-Blot Analysis
  • Tumors collected as described above are immediately snap-frozen in liquid nitrogen and stored at −80° C. Tumor tissues are homogenized on ice using a Daunce homogogenizer in an extraction buffer (25 mM Tris pH 7.5 containing the following protease inhibitors: 10 μg/mL leupeptin, 10μg /mL soybean tryp-chymotrypsin inhibitor, 10 μg/mL N-tosyl-L-phenylalanine chloromethyl ketone, 10 μg/mL aprotinin, Nα-p-tosyl-L-arginine methyl ester, 7 mM benzamidine, 0.3 mM phenylmethylsulfonyl fluoride and two tablets of Roche complete protease inhibitor cocktail; following phosphatase inhibitors: 60 mM beta-glycerophosphate, 1 mM sodium vanadate, 10 mM sodium fluoride. 20 nM p-nitrophenyl phosphate, 1 μM okadaic acid, 1 μM microcystin, 2.5 mM sodium pyrophosphoate; and 1 mM dithiothreitol, 15 mM EDTA, 5 mM EGTA, 1% Triton X100 and 150 mM NaCl).
  • Tissue lysates are cleared by centrifugation in a refrigerated microcentrifuge at 14,000 rpm and at 1° C. for 20 min. Supernatants are transferred to fresh microfuge tubes prechilled on ice and snap-freeze again in liquid nitrogen or dry ice. After quick thaw to about 80% completion in lukewarm water, the samples are placed on ice to complete thaw. The samples are centrifuged again at 14,000 rpm and at 1° C. for 15 min. The supernatant is transferred to fresh prechilled microfuge tubes and protein concentrations are measured using Bio-Rad protein assay reagents using bovine serum albumin as protein standard.
  • Protein extracts are equalized with the extraction buffer. An equal volume of 2× SDS sample buffer is added to the protein extracts and boiled in a waterbath for 5 min. 100 μg of protein extract per sample is used for electrophoresis on 4-20% gradient SDS-PAGE gel and transferred onto nitrocellulose (NC) membranes. NC membranes are blocked in 5% BSA in TBST (20 mM Tris pH=7.5, 500 mM NaCl, 0.05% Tween 20 and 0.02% sodium azide) for least 1 h. The membranes are then incubated in primary antibody at 1:1,000 with 5% BSA in TBST overnight on a shaker with 80 rpm at 4° C. Membranes are washed 4×, 10 min each, with TBST. The membranes are then incubated for 40 min with secondary antibody HRP (horse radish peroxidase) conjugate at 1:10,000 dilution in 3% non-fat milk in TBST and washed again 4 times with TB ST, 10 min each. The immuno-blots are then visualized by enhanced chemiluminescence (ECL, Amersham) as per manufacturer's instructions. All primary antibodies are purchased from Cell Signaling and secondary antibody HRP conjugates are obtained from Amersham. Gels, membranes and apparatus used for electrophoresis and Western blotting are purchased from Invitrogen. Protein bands of interest are quantified from films using Kodak Image Station 1000.
  • The compound of EXAMPLE 104 was tested essentially as described above and exhibited a TMED50=3.59 mg/kg
    • Rat Collagen Induced Arthritis Efficacy Model
  • Female Lewis rats (≡190 g, Charles River Labs) are immunized with Bovine type II collagen (2 mg/mL) emulsified with an equal volume of adjuvant (aluminum hydroxide). were used. The rats are immunized with approximately 0.3 mg of the emulsion intradermally on the back near the base of the tail. All animals are re-immunized 7 days later according to the same protocol. The rats begin to develop arthritis (characterized by swellling and redness of one or both ankles) from 12 to 14 days after the first immunization. The rats are equally distributed into five treatment groups at the first signs of arthritis and treatment is initiated with each rat dosed bid for 14 days.
  • Treatment groups:
  •
    Group 1 Vehicle (1% NaCarboxymethylcellulose + 0.25% Tween 80)
    1 mL, PO, Bid × 14 days
    Group 2 Test compound, 5 mg/kg, 1 mL, PO, Bid × 14
    Group 3 Test compound, 15 mg/kg, 1 mL, PO, Bid × 14
    Group 4 Test compound, 30 mg/kg, 1 mL, PO, Bid × 14
    Group 5 Prednisolone 10 mg/kg, 1 mL, PO, qd × 14
  • Ankle diameter is measured with calipers 5 days a week and recorded. Data is expressed as the area under the curve (AUC) generated from the composite inflammation scores and statistical analysis performed. The compound of EXAMPLE 104 was tested essentially as described above and exhibited a TMED50=1.5 mg/kg (b.i.d.).
  • Oral administration of the compounds of the present invention is preferred. However, oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine, and the intravenous route may be preferred as a matter of convenience or to avoid potential complications related to oral administration. Compounds of Formula I may also be administered by the percutaneous, intramuscular, intranasal or intrarectal route in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs, the convenience of the patient and the caregiver, and other relevant circumstances (Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).
  • The pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material that can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art. The pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants. suppositories, solutions, suspensions, or the like.
  • The compounds of the present invention may be administered orally, for example, with an inert diluent or capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of the compound of the present invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the compound present in compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations of the present invention may be determined by methods well known to the skilled artisan.
  • The tablets, pills, capsules, troches, and the like may also contain one or more of the following adjuvants: binders such as povidone, hydroxypropyl cellulose, microcrystalline cellulose, or gelatin; excipients or diluents such as: starch, lactose, microcrystalline cellulose or dicalcium phosphate, disintegrating agents such as: croscarmellose, crospovidone, sodium starch glycolate, corn starch and the like; lubricants such as: magnesium stearate, stearic acid, talc or hydrogenated vegetable oil; glidants such as colloidal silicon dioxide; wetting agents such as: sodium lauryl sulfate and polysorbate 80; and sweetening agents such as: sucrose, aspartame or saccharin may be added or a flavoring agent such as: peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials that modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, hydroxypropyl methylcellulose, polymethacrylates, or other coating agents. Syrups may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
  • The compounds of Formula I are generally effective over a wide dosage range. For example, dosages per day normally fall within the range of about 0.0001 to about 30 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Claims (5)

1-10. (canceled)
11. A method of treating breast cancer comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula:
Figure US20090318443A1-20091224-C00018
where:
W is:
Figure US20090318443A1-20091224-C00019
X is N, or C-R1;
R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
R1 is hydrogen, amino, methyl, or —N=CH(NMe)2;
R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
R4 is hydrogen or C1-C7 alkyl;
R5 and R6 are independently selected from the group consisting of C1-C7 alkyl; or a pharmaceutically acceptable salt thereof.
12. A method of treating breast cancer comprising administering to a mammal in need of such treatment an effective amount of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate.
13. A method of treating prostate cancer comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula:
Figure US20090318443A1-20091224-C00020
where:
W is:
Figure US20090318443A1-20091224-C00021
X is N, or C-R1;
R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), —SO2—(C1-C7 alkyl), or —SO2—NR5R6;
R1 is hydrogen, amino, methyl, or —N=CH(NMe)2;
R2 is phenyl optionally substituted with one or two substituents independently selected from halo;
R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl;
R4 is hydrogen or C1-C7 alkyl;
R5 and R6 are independently selected from the group consisting of C1-C7 alkyl; or a pharmaceutically acceptable salt thereof.
14. A method of treating prostate cancer comprising administering to a mammal in need of such treatment an effective amount of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate.
US12/509,886 2004-01-30 2009-07-27 Kinase inhibitors Abandoned US20090318443A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/509,886 US20090318443A1 (en) 2004-01-30 2009-07-27 Kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54083004P 2004-01-30 2004-01-30
US10/597,283 US7582652B2 (en) 2004-01-30 2005-01-25 Kinase inhibitors
PCT/US2005/000025 WO2005075478A1 (en) 2004-01-30 2005-01-25 Kinase inhibitors
US12/509,886 US20090318443A1 (en) 2004-01-30 2009-07-27 Kinase inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/597,283 Continuation US7582652B2 (en) 2004-01-30 2005-01-25 Kinase inhibitors
PCT/US2005/000025 Continuation WO2005075478A1 (en) 2004-01-30 2005-01-25 Kinase inhibitors

Publications (1)

Publication Number Publication Date
US20090318443A1 true US20090318443A1 (en) 2009-12-24

Family

ID=34837430

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/597,283 Expired - Fee Related US7582652B2 (en) 2004-01-30 2005-01-25 Kinase inhibitors
US12/509,886 Abandoned US20090318443A1 (en) 2004-01-30 2009-07-27 Kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/597,283 Expired - Fee Related US7582652B2 (en) 2004-01-30 2005-01-25 Kinase inhibitors

Country Status (25)

Country Link
US (2) US7582652B2 (en)
EP (1) EP1713805B1 (en)
CN (1) CN100516064C (en)
AR (1) AR047466A1 (en)
AT (1) ATE433449T1 (en)
AU (1) AU2005210459B2 (en)
CA (1) CA2559128C (en)
CY (1) CY1109234T1 (en)
DE (1) DE602005014848D1 (en)
DK (1) DK1713805T3 (en)
DO (1) DOP2005000010A (en)
ES (1) ES2326819T3 (en)
IL (1) IL178103A (en)
MY (1) MY143516A (en)
NZ (1) NZ549780A (en)
PE (1) PE20050689A1 (en)
PL (1) PL1713805T3 (en)
PT (1) PT1713805E (en)
RU (1) RU2348635C2 (en)
SI (1) SI1713805T1 (en)
SV (1) SV2006002001A (en)
TW (1) TWI332003B (en)
UA (1) UA85505C2 (en)
WO (1) WO2005075478A1 (en)
ZA (1) ZA200607648B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281865A1 (en) * 2010-05-17 2011-11-17 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AR083868A1 (en) * 2010-12-03 2013-03-27 Lilly Co Eli OXAZOL COMPOUNDS [5,4-B] PIRIDIN-5-ILO
PT2780011T (en) * 2011-11-11 2018-05-14 Lilly Co Eli COMBINATION THERAPY FOR OVARIAN CANCER
WO2014018509A1 (en) * 2012-07-23 2014-01-30 The University Of Akron Polyisobutylene-based polyurethanes containing organically modified montmorillonite
TWI731317B (en) 2013-12-10 2021-06-21 美商健臻公司 Tropomyosin-related kinase (trk) inhibitors
TN2017000234A1 (en) 2014-12-18 2018-10-19 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
AU2016226468B2 (en) 2015-03-02 2020-10-22 Bristol-Myers Squibb Company TGF-beta inhibitors
RS63581B1 (en) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc P38 KINASE INHIBITORS REDUCE THE EXPRESSION OF DUX4 AND DOWNSTREAM GENES TO TREAT FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10899869B2 (en) 2019-01-24 2021-01-26 The University Of Akron Glycerol containing polyurethanes and polyurethane nanocomposites
TW202112368A (en) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 Inhibitor combinations for treatment of diseases related to dux4 expression
IL315722A (en) 2022-03-23 2024-11-01 Ideaya Biosciences Inc Piperazine substituted indazole compounds as inhibitors of parg

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5685455A (en) * 1994-02-11 1997-11-11 Bernhardt Apparatebau Gmbh U. Co. Device for inflating a container or a floating body, more particularly a life jacket
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6335340B1 (en) * 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6335336B1 (en) * 1997-05-22 2002-01-01 G.D. Searle & Company 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6414150B1 (en) * 1996-08-21 2002-07-02 Smithkline Beecham Corporation 4,5-disubstituted imidazole compounds
US6426360B1 (en) * 1994-07-28 2002-07-30 G D Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
US6696434B2 (en) * 1997-05-28 2004-02-24 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US7582652B2 (en) * 2004-01-30 2009-09-01 Eli Lilly And Company Kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (en) 1992-01-13 1994-07-29 Smithkline Beecham Corp NOVEL IMIDAZOLE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
WO1999000130A1 (en) 1997-06-30 1999-01-07 Temple University - Of The Commonwealth System Of Higher Education Method for treating vulvar vestibulitis
AR016294A1 (en) * 1997-07-02 2001-07-04 Smithkline Beecham Corp IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6291457B1 (en) 1999-07-01 2001-09-18 Merck & Co., Inc. Compounds having cytokine inhibitory activity
DE60024480T2 (en) * 1999-10-27 2006-07-27 Novartis Ag THIAZOL AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
WO2002072579A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
PL367325A1 (en) 2001-04-16 2005-02-21 Tanabe Seiyaku Co, Ltd. Large conductance calcium-activated k channel opener
WO2003062215A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
MXPA05001389A (en) 2002-08-06 2005-04-28 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5685455A (en) * 1994-02-11 1997-11-11 Bernhardt Apparatebau Gmbh U. Co. Device for inflating a container or a floating body, more particularly a life jacket
US6426360B1 (en) * 1994-07-28 2002-07-30 G D Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6414150B1 (en) * 1996-08-21 2002-07-02 Smithkline Beecham Corporation 4,5-disubstituted imidazole compounds
US6335336B1 (en) * 1997-05-22 2002-01-01 G.D. Searle & Company 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6696434B2 (en) * 1997-05-28 2004-02-24 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6335340B1 (en) * 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US7582652B2 (en) * 2004-01-30 2009-09-01 Eli Lilly And Company Kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chen et al., Cancer res (2009), vol. 69(23), pages 8853-8861. *
Olson et al., opinion trends in molecular medicine, vol. 10(30, (2004), pages 125-129. *
Roberts et al., Oncogene (2007), 26, pages 3291-3310. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281865A1 (en) * 2010-05-17 2011-11-17 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US8481739B2 (en) * 2010-05-17 2013-07-09 Incozen Therapeutics Pvt. Ltd. 3,5-Disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H[1,2,3]triazolo [4,5-b] Pyridine Compounds as Modulators of protein kinases

Also Published As

Publication number Publication date
RU2006138606A (en) 2008-05-10
AR047466A1 (en) 2006-01-18
DK1713805T3 (en) 2009-08-17
TWI332003B (en) 2010-10-21
ATE433449T1 (en) 2009-06-15
EP1713805A1 (en) 2006-10-25
CY1109234T1 (en) 2014-07-02
ES2326819T3 (en) 2009-10-20
HK1100141A1 (en) 2007-09-07
MY143516A (en) 2011-05-31
NZ549780A (en) 2010-01-29
AU2005210459B2 (en) 2010-10-21
US20090036445A1 (en) 2009-02-05
SV2006002001A (en) 2006-02-15
WO2005075478A1 (en) 2005-08-18
CN100516064C (en) 2009-07-22
PE20050689A1 (en) 2005-09-27
AU2005210459A1 (en) 2005-08-18
IL178103A (en) 2011-04-28
CN1938302A (en) 2007-03-28
PT1713805E (en) 2009-08-20
UA85505C2 (en) 2009-01-26
SI1713805T1 (en) 2009-10-31
RU2348635C2 (en) 2009-03-10
DE602005014848D1 (en) 2009-07-23
US7582652B2 (en) 2009-09-01
CA2559128C (en) 2013-04-16
DOP2005000010A (en) 2005-11-15
TW200526660A (en) 2005-08-16
CA2559128A1 (en) 2005-08-18
EP1713805B1 (en) 2009-06-10
ZA200607648B (en) 2008-06-25
PL1713805T3 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
US20090318443A1 (en) Kinase inhibitors
US7320995B2 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
US7863310B2 (en) Kinase inhibitors
CA2634787C (en) Azaindole inhibitors of aurora kinases
US10022374B2 (en) Certain protein kinase inhibitors
US5354759A (en) Angiotenin II antagonizing heterocyclic compounds
AU2018391833A1 (en) Compound functioning as bromodomain protein inhibitor, and composition
AU2013276519B2 (en) 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
NO178697B (en) Analogous Process for Preparing Therapeutically Active Pyrazolopyridine Compounds
BG61342B1 (en) New oxazolyl derivatives
JP5662319B2 (en) Aza-benzimidazolone chymase inhibitor
CN112778275A (en) Adamantyl PRMT5 inhibitor and application thereof
EP2391624B1 (en) Azaquinazolinediones useful as chymase inhibitors
JP3239506B2 (en) Heterocyclic derivatives
JPH02117675A (en) Pyridoindol derivative and production thereof
HK1100141B (en) Kinase inhibitors
JP2024506814A (en) Quinoline and azaquinoline as CD38 inhibitors
WO2014141118A1 (en) Imidazo[4,5-c]quinoline derivatives and uses thereof
CN119019402A (en) Polycyclic compounds as LRRK2 kinase inhibitors and preparation methods and uses thereof
HK1218119B (en) Certain protein kinase inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION